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Definitions 
Drugs/Illicit substances: Drugs that are illegal to use or deposit in Norway. 
Euthymic: A normal mood state, neither depressive nor elevated. 
Excessive substance use: DSM-IV substance use disorder or predominantly daily use of alcohol 
and/or predominantly weekly use of drugs (other than alcohol) during a period of at least 4 years.  
Sequencing of onsets: The temporal relationship between the onset of BD and the (possible) onset 
of excessive substance use: 
Primary BD: When there has been no excessive substance use prior to the onset of BD. 
Secondary BD: When excessive substance use precedes the onset of the BD. 
Substance use disorder: DSM-IV substance abuse or dependence 
Substances: Drugs and alcohol 
The outcome of BD: Clinical and functional characteristics related to both illness course and current 
status. 
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1 INTRODUCTION 
1.1 General introduction 
1.1.1 Bipolar disorder 
Bipolar disorder (BD) is a severe mental illness causing significant individual suffering and 
functional loss. It is characterized by severe mood swings; periods with distinctly depressed and 
elevated mood in between periods with normal mood (euthymia). Melancholy (i.e. depression) and 
mania were first described by the ancient Greeks and are thus among the oldest reported of 
human illnesses. While Hippocrates (460-337 BC) was the first to systematically describe mania and 
melancholia, the first known writings of these two phenomena as part of the same disease dates 
back to the 1st century AD. Around 1850, BD was for the first time formulated as a separate entity 
of mental disorder by Jean-Pierre Falret: “la folie circulaire”(Angst & Marneros, 2001). The concept 
of “manic-depressive insanity” was developed by Kraepelin towards the end of the 19th century and 
included both recurrent depression (without mania), manic, hypomanic and mixed episodes 
(Kraepelin, 1899).  
It was not until the midst of the 20th century that a distinction between recurrent 
depressions only (unipolar disorder) and recurrent manias with depressions (bipolar disorder) was 
made. This distinction was incorporated in the international diagnostic system Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-III (American Psychiatric Association, 1980), and has 
persisted since then. In 1976, Dunner and co-workers distinguished BD I from BD II on the basis of 
differences in course and family history of affective symptomatology (Dunner et al., 1976), 
although the latter has been questioned by later studies (Edvardsen et al., 2008). Today, in the 
fourth edition of the DSM (DSM-IV), BD comprises BD I, BD II, cyclothymia and BD NOS (Not 
Otherwise Specified) (American Psychiatric Association, 1994). The other diagnostic system, the 
International Classification of Diseases, has similar diagnostic criteria for BD (World Health 
Organization, 2004). There are, however, minor differences such as the requirement of more than 
one affective episode in the ICD-10 as opposed to the DSM-IV, where one manic episode is 
sufficient to fulfill BD I criteria. In this thesis, the DSM-IV is used. 
1.1.2 Substance use and use disorders 
The use of psychoactive substances, i.e. substances that act on the central nervous system and 
alters brain functioning may have been part of human behavior and culture since the emergence of 
our species (Durrant & Thakker, 2003). Alcohol and drugs are used in most countries of the world 
10 
 
today, but the extent and patterns of use vary between countries and cultures and over time. 
Alcohol and drug use are estimated to be responsible for approximately 5% of the global burden of 
disease (Rehm et al., 2006). Since the 1980’s, there has been a substantial increase in the 
production and use of illicit drugs throughout the world, with important consequences for public 
health (World Health Organization, 2000). In a prevalence study of seven international sites 
(Europe, North- and Latin America), the percentage of the population that reported lifetime use of 
alcohol was in the range of 43-86%, the lifetime use of cannabis five or more times ranged from 2-
30%, and the lifetime use of other drugs ranged from 2-19% (Vega et al., 2002).  
Substance use may progress from use to addiction, which is usually defined as a persistent, 
compulsive and uncontrolled dependence of a substance. Research has made considerable 
progress the last decades in gaining knowledge on the psychobiological mechanisms by which 
substance use is reinforced and addiction develops (Koob & Le Moal, 2001). Substance use 
disorders (SUD) were included as mental disorders in the DSM since the first edition (American 
Psychiatric Association, 1952). In the DSM-IV, substance use is considered as a disorder when it 
implies a “maladaptive pattern of substance use which leads to substantial clinical discomfort or 
functional loss”. The diagnostic system subdivides SUDs into two disorders with increasing severity: 
substance abuse and substance dependence, characterized by two different sets of symptom 
criteria. Abuse is defined by negative consequences of social, forensic or risk behavioral character. 
Dependence is defined by two major characteristics: a compulsion to take the drug with a 
narrowing of the behavioral repertoire toward excessive drug intake, and a loss of control in 
limiting intake. The most severe type of dependence, often referred to as addiction, is signified by a 
physiological dependence involving tolerance and withdrawal symptoms. This is more likely for 
some drugs (alcohol, cocaine and opioids) than for others (hallucinogens). According to the DSM-
IV, the symptoms of abuse or dependence must have been present within the same year in order 
to fulfill diagnostic criteria. Enduring excessive use is necessary in order to develop dependence. 
Regarding abuse, the substance related problems must have occurred repeatedly or been 
persistent (American Psychiatric Association, 1994).  
1.1.3 The close relationship between bipolar disorder and substance abuse 
More than a century ago, a high co-occurrence of alcohol abuse among patients with BD was noted 
by Kraepelin (Goodwin et al., 2007). Since then clinical and epidemiological studies across different 
populations have confirmed this observation (Cassidy et al., 2001; Grant et al., 2005; Regier et al., 
1990). In fact, the rates of SUD appear to be higher in BD than in most other psychiatric disorders. 
The mechanisms behind this common co-occurrence are largely unknown, and although substantial 
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effort to gain knowledge on important aspects of this relationship has been made in research the 
last decades, several issues remain unclear. The current study aims at clarifying some of these 
issues. 
1.2 Bipolar disorder 
1.2.1 The diagnostic criteria 
Diagnostic systems for mental disorders are descriptive, implying that it is based on the patient’s 
experiences, thoughts and behavior. The DSM-IV criteria were established in 1994 by an expert 
committee, and extensive work has been conducted to ensure the diagnoses’ validity and 
reliability. The diagnostic systems of today are categorical, in the sense that a diagnosis is given 
only if sufficient criteria for the disorder are met, and polythetic, i.e. patients within a category 
have some, but not necessarily all characteristics in common. 
BD comprises depressive, hypomanic, manic and/or mixed episodes (diagnostic criteria for 
the episode subtypes are presented in Table 1 in the Appendix). A BD I diagnosis may be given on 
the basis of manic episodes only, while in BD II, at least one hypomanic episode and one major 
depressive episode are required to fulfill diagnostic criteria. The diagnosis of BD NOS refers to 
bipolar symptoms that do not fulfill criteria for a specific BD (i.e. episodes of shorter length or cases 
in which it cannot be determined whether the BD is primary or secondary to a somatic state or 
substance use) (American Psychiatric Association, 1994). During the recent years, attempts have 
been made to differentiate between several additional BD subtypes. However, the main focus now 
seems to be on a natural continuum from transient to persistent manic manifestations of varied 
length, severity and frequency (Angst & Marneros, 2001). During the recent years, there has also 
been a movement towards a more dimensional diagnostic system for severe mental disorders, 
based on the increasing empirical evidence for considerable overlap in both the clinical, genetic, 
neuropathological and neurocognitive features of bipolar disorder and schizophrenia (Craddock & 
Owen, 2007; Murray et al., 2004). This view is also supported by previous findings from our 
research group (Simonsen et al., 2009). 
1.2.2 Epidemiology 
The lifetime prevalence of BD is generally stated to be 1% for BD I and 1-2% for BD II, with 
somewhat more uncertain rates for BD II due to difficulties distinguishing hypomania from normal 
mood-fluctuations in community samples (Goodwin et al., 2007; Kessler et al., 2007). The 
prevalence of BD is believed to be relatively consistent across cultures and regions, however, 
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prevalence rates vary from 0.1 - 1.8% for bipolar I disorder and 0.3 - 3.0% for bipolar II disorder 
across studies (Angst, 1998; Sherazi et al., 2006; Weissman et al., 1996). It is not known whether 
this variation is caused by differences in methodology or by actual variation across populations.  
1.2.3 Biological and neurocognitive abnormalities 
Our understanding of the pathophysiology of BD remains limited. However, several neurobiological 
abnormalities have been identified that are likely to be underlying features of the disorder, such as 
immunological, neuroendocrinological, and molecular biological deviations (Langan & McDonald, 
2009). Furthermore, neuroimaging and post mortem studies have identified both structural and 
functional disturbances in brain areas involved in the regulation of emotions and motivated 
behavior as well as cognition, such as regions in the prefrontal and orbitofrontal cortex, and the 
amygdala and ventral striatum (Phillips et al., 2008). Structural abnormalities of the CNS appear to 
be more pronounced in BD I than BD II; in a recent study from the TOP study group, only BD I 
patients showed cortical thinning in several brain regions, while BD I and II combined showed 
several substantial subcortical volume reductions relative to healthy controls (Rimol et al., 2010). 
BD patients, even during euthymic periods, also show neurocognitive impairment in a number of 
domains, the largest seen in aspects of executive function and verbal memory (Robinson et al., 
2006). The severity of neurocognitive deficits is positively correlated with illness duration and 
number of previous manic episodes (Martinez-Aran et al., 2004). Furthermore, in a previous study 
from our group patients with BD I were shown to be more severely affected neurocognitively than 
patients with BD II (Simonsen et al., 2008), although the severity of impairments was more strongly 
related to the presence of lifetime psychotic symptoms than to the bipolar diagnostic subtype 
(Simonsen et al., 2009). Neurobiological and neuropsychological phenomena are beyond the scope 
of this thesis, and will thus not be discussed in further detail. 
1.2.4 Etiology 
The etiology of BD is still to a large extent unknown, but family- and twin-studies have provided 
strong evidence that vulnerability to the disorder is genetically transferred (Smoller & Finn, 2003), 
with heritability estimates around 0.8 (Kendler et al., 1995). Multiple genes or complex genetic 
mechanisms appear to be involved. Recent genome-wide association studies have identified some 
gene variations that influence susceptibility to BD, although effect sizes are small (Craddock et al., 
2009; Djurovic et al., 2010).  
Since the monozygotic twin concordance rate is far below 100% (38.5 - 62%) (Smoller & 
Finn, 2003), environmental factors must influence the phenotype. Even though research so far is 
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limited, there is evidence that childhood trauma (Garno et al., 2005), stressful life events (Horesh & 
Iancu, 2010), cannabis use (van Laar et al., 2007) and migration (Swinnen & Selten, 2007) are 
associated with heightened risk for BD. Virus infections and obstetric complications have also been 
suggested as potential environmental risk factors, although current evidence seems week (Scott et 
al., 2006; Yolken & Torrey, 1995). Thus, BD appears to develop from an interaction between 
genetic, neurobiological and environmental factors. 
The stress-vulnerability model 
The notion that environmental factors are risk factors for BD is in part based on stress-vulnerability 
models. Such models have been postulated for psychiatric disorders in general and more 
specifically for affective and psychotic disorders (Harris & Brown, 1989; Nuechterlein & Dawson, 
1984; Post et al., 1986; van Winkel et al., 2008). Stress-vulnerability models generally suppose that 
psychiatric symptoms emerge whenever a threshold of stressors exceeds an individual’s 
vulnerability level, conceptualized as a stable within-person characteristic (van Winkel et al., 2008). 
The notion of vulnerability is however complex and difficult to define and measure, and includes 
features such as family history, different biological factors, personality or behavioral attributes and 
experiences of damaging circumstances in the past. The most commonly used vulnerability marker 
for BD is a family history of affective disorder among close relatives. However, an experienced 
stressor may also increase an individual’s vulnerability in that it subsequently enhances the 
individual’s stress sensitivity. This notion is conceptualized in the behavioral sensitization model for 
BD (Post, 1992).  
 
The kindling and behavioral sensitization models for bipolar disorder 
Life events seem to play a role not only in the onset of the first affective episode, but also in 
relapses (Hammen & Gitlin, 1997; Kennedy et al., 1983). However, early clinical observations have 
indicated that the role of environmental stressors is greater for initial than later episodes of mania 
and depression (Kraepelin, 1921). This phenomenon has formed the basis for electrophysiological 
kindling (progressive vulnerability to seizures) and behavioral sensitization (progressive change in 
psychomotor stimulant response) as analogous models for the course of affective disorders (Post 
et al., 1986). The kindling model suggests that stressful events trigger the first affective episodes 
while later episodes may eventually become independent from external events. Behavioral 
sensitization provides a model for the development of the increasingly severe and rapid 
recurrences seen in a subgroup of patients in response to repeated stress of equal or reduced 
magnitude (Post et al., 1986; Post, 1992). Furthermore, there are also indications of cross-
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sensitization, in that one type of stimulus (e.g. psychosocial stress) increases the sensitivity for 
other types of stimuli (e.g. substance use) (Swann, 2010). Several phenomena appear to support 
these models: the fact that affective disorder is recurrent for the majority of patients, the tendency 
for reduced cycle length (time between episodes) with increasing number of prior episodes in 
some patients (Kessing & Andersen, 2005), and the greater prevalence or severity of life events 
preceding the first affective episode compared to later episodes (Ambelas, 1987). However, later 
identification of methodological flaws in some of the studies as well as inconsistencies in recent 
findings (Dienes et al., 2006; Hlastala et al., 2000; Johnson et al., 2000), leave unresolved questions 
regarding the validity of these models. 
1.2.5 Course and implications 
Illness course and comorbidity 
Bipolar disorder usually has its onset in the early twenties to the early thirties (Goodwin et al., 
2007). It is a highly recurrent and chronic disorder. Even though substantial improvement in 
remission and relapse rates is achieved with mood-stabilizing medication such as lithium, 
antipsychotic and anti-epileptic agents, approximately 75% of patients relapse within five years 
when followed along in naturalistic treatment settings (Gitlin et al., 1995). The ratio of time spent 
with depressive relative to manic symptoms appears to be 3:1, and patients experience affective 
symptoms approximately half of the time (Judd et al., 2002). Patients also appear to spend more 
time with subsyndromal affective symptoms than in episodes (Joffe et al., 2004). However, only a 
subgroup of patients seem to develop progressive cycle-acceleration over the course of illness 
(Salvatore et al., 2007). As the acute manic episodes are more severe in BD I compared to 
hypomania in BD II, BD I is considered to be a more severe illness. However, the overall disease 
burden may be similar for the two bipolar subtypes, since BD II appears to have a more chronic and 
predominantly depressive course compared to BD I (Judd et al., 2003). 
Comorbid medical disorders and -risk factors with increased mortality rates and shorter life 
span is also common in BD (Birkenaes et al., 2007; McIntyre et al., 2007). Furthermore, in addition 
to high rates of substance use disorders (McElroy et al., 2001), several comorbid psychiatric 
disorders such as personality disorders and anxiety disorders are frequent (Fan & Hassell, 2008; 
Grant et al., 2005).  
Suicidal behavior  
From 10% to 56% of individuals with BD attempt suicide at least once during their lives (Goodwin 
et al., 2007). The total risk for death by suicide in BD has been estimated to approximately 20%, 
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which is more than 20-fold higher than in the general population (Tondo et al., 2003) and accounts 
for a considerable proportion of the excess mortality in BD. Suicidal behavior is more frequent early 
in the illness course (Ösby et al., 2001; Tondo et al., 2007) and in association with depressive 
episodes (Isometsä et al., 1994). Rates appear to be similar for BD I and II (Novick et al., 2010), 
however, there is evidence that suicide acts are more lethal in BD II compared to BD I (Tondo et al., 
2007).  
Functional loss in bipolar disorder 
Bipolar disorder is among the 10 leading causes of disability-adjusted life years (years of life lost to 
premature death and years lived with disability) among 15-44 year olds in the world (World Health 
Organization, 2001). BD implies compromised functioning in several domains even with sustained 
recovery. One study showed that while 98% of the patients attained syndromal recovery 2 years 
after the first episode, only 31% reached functional recovery (defined as return to baseline 
vocational status and living situation) (Tohen et al., 2000). Reduced functioning in BD is also seen in 
marriage rates (Mitchell et al., 2009) and in social and leisure activities (Blairy et al., 2004). Several 
studies have also shown that individuals with BD have reduced quality of life compared to healthy 
controls (Michalak et al., 2005). In a recent study from the TOP study group, BD patients rated 
themselves on the same level of social functioning as did the schizophrenia patients, both groups 
significantly lower than healthy controls (Simonsen et al., 2010). BD I and II also appear to have a 
similar level of impairment in psychosocial functioning (Ruggero et al., 2007). Functional 
impairment is primarily associated with clinical characteristics (comorbidity, symptom severity etc.) 
but also with neurocognition (Sanchez-Moreno et al., 2009), also supported by previous findings 
from our study group (Simonsen et al., 2010). Despite all indications of impaired functioning, there 
is biographical evidence that BD is associated with creativity and scholastic achievement (Jamison, 
1995). The scientific evidence for such an association has been weak, but a higher educational level 
among BD patients compared to the general population has been found (Mitchell et al., 2009), and 
in a recent prospective epidemiologic study excellent school performance was associated with a 
fourfold increase in the risk for later BD (MacCabe et al., 2010). How these findings converge with 
the neurocognitive impairment associated with BD is largely unknown, but may be related to a 
deteriorating effect of recurrent affective episodes on cognition (Ferrier & Thompson, 2002). 
Treatment of bipolar disorder 
Until the therapeutic benefits of lithium were discovered in the midst of the 20th century, there was 
no efficacious treatment for BD. Later, anticonvulsants and antipsychotic agents have also proved 
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effective, and along with lithium these medications are recommended treatments of BD according 
to today’s expert consensus guidelines (Grunze et al., 2004). However, pharmacological treatments 
are still suboptimal, especially regarding functional impairment, which has lead to the development 
and adjustment of several psychotherapeutic interventions for BD, such as psychoeducation, 
Interpersonal and Social Rhythm Therapy, cognitive behavioral therapy and family therapy. These 
have all shown promising results in reducing recurrence rates, hospitalizations and functional 
impairment (Colom et al., 2003; Miklowitz & Scott, 2009).  
1.3 Substance use and abuse in bipolar disorder 
1.3.1 The prevalence of substances use disorders in bipolar disorder  
Substance use seems to be a particular problem in BD, recognized in both epidemiological and 
clinical studies. The Epidemiological Catchment Area study conducted in the USA in the 1980’s 
reported higher prevalences of SUDs in BD than in other Axis I disorders (including schizophrenia, 
anxiety disorders and other affective disorders), with a lifetime prevalence of 46% for alcohol use 
disorders and 41% for drug use disorders (Regier et al., 1990). In the more recent NESARC study, 
the reported prevalences were 58% and 38% respectively (Grant et al., 2005). With the starting 
point in the SUDs, another epidemiological study reported that the lifetime risk for mania was 
increased with an odds ratio of 9.7 in persons with alcohol dependence and 8.4 in drug 
dependence (Kessler et al., 1996). Alcohol use disorders are more prevalent in men than in women, 
but when compared to prevalence rates in the general population, the risk for developing alcohol 
use disorders in BD is considerably greater for women than for men (Frye et al., 2003).  
In clinical studies of BD I samples reporting the prevalence for all major substance use 
disorders separately, the lifetime rates range from 36 to 49% for alcohol, 17 to 36% for cannabis, 4 
to 22% for stimulants (cocaine and amphetamines), 3 to 9% for opiates, 3 to 7% for sedatives and 4 
to 7% for hallucinogens (Cassidy et al., 2001; Goldberg et al., 1999; McElroy et al., 2001; Pini et al., 
1999; Winokur et al., 1998). These rates clearly exceed that of the general population. The 
prevalence of different SUDs in BD II disorder is less investigated. To the best of my knowledge, 
only two studies have investigated rates for all major lifetime substance use disorders in BD II, and 
these report the following rates: 22 and 39% for alcohol, 10 and 6% for cannabis, 6 and 6% for 
stimulants, 4 and 6% for cocaine, 0 and 0% for opiates, 2 and 6% for sedatives and 2 and 6% for 
hallucinogens (Chengappa et al., 2000; McElroy et al., 2001). Thus, the rates appear to be 
somewhat lower in BD II compared to BD I, but the differences are not prominent. 
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Possible reasons for differences in SUD prevalence 
The prevalence rates of SUD in BD vary widely across different geographical settings, from 49% 
with alcohol- and 44% with drug use disorders in a study from the US (Cassidy et al., 2001), through 
28% with alcoholism and 14% with drug addiction in a study from Brazil (Neves et al., 2009) to 10% 
with alcohol use disorders and none with drug use disorders in a study from Taiwan (Tsai et al., 
1997). Such variations could be reflecting differences in substance use in the general populations 
from which the BD samples are recruited, but could also be related to different methodologies 
used in these studies. To my knowledge, there has been only one multinational study of substance 
misuse in BD where a common methodology was used across sites, reporting higher prevalence 
rates in the US than in Europe (Germany/Netherlands) (47% vs. 27%) (Post et al., 2008). Still, most 
studies investigating the prevalence of SUD in BD are conducted in the US where the rates of illicit 
drug use in the general population are relatively high compared to other countries (Vega et al., 
2002). Thus, there is a need for prevalence studies conducted in other countries than the US, 
preferably comparing the substance use of BD subjects with that of a reference population from 
the same geographical area and within the same time period. In the current study, the prevalence 
of lifetime use of illicit substances in a sample of BD patients is compared to that of the general 
population. 
1.3.2 Excessive substance use in bipolar disorder 
Most studies of the consequences of substance use in BD have only investigated substance use that 
meets diagnostic SUD criteria. Investigating a broader range of substance use could be relevant 
because people with severe mental disorders appear to be more sensitive to and more likely to 
experience negative consequences also from using relatively small amounts of psychoactive 
substances, compared to healthy individuals (Bizzarri et al., 2007; Mueser et al., 1998). For 
instance, euthymic individuals with BD had increased behavioral response to intravenous 
amphetamine compared to healthy controls in an experimental study (Anand et al., 2000). In BD, 
moderate alcohol consumption has been shown to be associated with more severe manic 
symptoms compared to abstinence, and to poorer social and familial adjustment and increased 
health-care use (Goldstein et al., 2008). Thus, in patients with severe mental illness, negative 
consequences from substance use may occur long before symptoms of abuse or dependence have 
developed. There has recently been increasing focus on including also substance use not fulfilling 
SUD criteria when investigating the impact of substance use on illness onset and clinical outcomes 
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in severe mental disorders (Goldstein et al., 2008; Henquet et al., 2006; Ringen et al., 2008; Ringen 
et al., 2009). However, little is still known regarding what level of use – i.e. amount and/or 
frequency - should be considered as excessive use in BD.  
Investigating substance use in BD patients without SUD may also increase our 
understanding of the psychopathology underlying the increased risk of abuse or dependence. 
Whether the propensity to substance use is part of the BD itself or something that characterizes 
only a subgroup is still unclear. To the best of my knowledge, only one study has assessed excessive 
substance use in BD, reporting that 46% had SUDs, and 8% had SUD-subthreshold substance use. In 
addition, the authors indicated that another substantial proportion used illicit substances 
occasionally (Sbrana et al., 2005). We thus need more knowledge on the prevalence of SUD-
subthreshold substance use in BD. The present study aims to assess the prevalence of substantial 
substance use that falls below the cut-off of DSM-IV diagnostic criteria. In this thesis, excessive use 
is defined not only by the existing SUD criteria (i.e. criteria including consequences of use), but also 
by criteria based on frequency and duration of use.  We also investigate differences and similarities 
in characteristics of both substance use and clinical characteristics between patients with SUD, 
patients with SUD-subthreshold substance use and patients with neither, to explore if also 
substance use below the SUD threshold appears to be harmful for patients with BD. 
1.3.3 Hypotheses for the co-occurrence of SUD and psychiatric disorders 
Comorbidity with SUDs is also common in other psychiatric disorders. The highest prevalence of 
SUDs is found in personality disorders such as antisocial and borderline personality disorders (Sher 
& Trull, 2002), but it is also high in other symptom disorders such as schizophrenia (Swartz et al., 
2006), major depressive disorder and anxiety disorders (Kessler et al., 1997). Thus, a close 
relationship appears to exist between SUDs and psychiatric disorders in general. Research also 
indicates that many of the individual factors that influence the susceptibility to develop SUDs, for 
instance genetics (Goldman et al., 2005), personality traits (such as novelty-seeking) (Fergusson et 
al., 2008), stress (Campbell et al., 2009; Sinha, 2008) and coping skills (Anderson et al., 2006) are 
linked to a general vulnerability for psychopathology. 
There are several hypotheses on the association between severe mental illness (including 
BD) and SUDs, and these can be organized into four general models: 1) common factor models, 2) 
secondary SUD models, 3) secondary psychiatric disorder models, and 4) bidirectional models 
(Mueser et al., 1998). Briefly, the common factor models hypothesize that risk factors are shared 
between the two disorders (e.g. genes, personality traits). The secondary SUD models suggest that 
severe mental illness increases the risk of developing SUDs (e.g. as an attempt to self-medicate 
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psychiatric symptoms). Secondary psychiatric disorder models propose that SUDs may trigger 
severe mental illness in individuals that would not otherwise have developed the disorder, and 
bidirectional models hypothesize that either disorder increases the vulnerability for the other 
disorder through ongoing interactional effects (Mueser et al., 1998). All models have gained some 
support from research on SUD and BD comorbidity, and they are not mutually exclusive but may 
account for parts of the comorbidity within groups and individuals. 
1.3.4 The effect of substance use on the outcome of bipolar disorder 
As substance use is known to alter affective states, and substance dependence to cause long-
lasting changes in brain regulatory mechanisms (Koob & Le Moal, 2001), substance use may be 
expected to act negatively upon the symptoms and course of BD. Accordingly, there is growing 
evidence that SUDs have a negative impact on aspects of the BD. However, the research literature 
tends to report this impact as broad and global, instead of being specific regarding which areas 
where excessive substance use seems to have an impact. Areas of interest here are both affective 
symptoms, illness course (number of episodes, hospital admissions etc.), and functional status 
including occupational status and global functioning. There is relatively consistent evidence that BD 
patients with SUD have slower recovery and faster relapses (Keller et al., 1986; Tohen et al., 1990), 
as well as elevated rates of suicidality (Cardoso et al., 2008) and medication non-adherence (Bauer 
et al., 2005) compared to patients without SUD. Other relatively consistent findings are that BD 
patients with SUD do not have an increased prevalence of psychotic symptoms (Verduin et al., 
2005) nor an increased number of affective episodes (Nolen et al., 2004) compared to BD without 
SUD. Findings are however more diverging regarding the rates of rapid cycling (Haro et al., 2006; 
MacKinnon et al., 2003), mixed episodes (Goldstein et al., 2008; Himmelhoch et al., 1976), the 
severity of affective symptoms (Salloum et al., 2002; Sonne et al., 1994) and the number or length 
of hospital admissions (Pini et al., 1999; Singh et al., 2005), where some studies find that these are 
increased in BD with SUD compared to BD without, and some find that they are not. Regarding 
functional variables such as global functioning (O'Connell et al., 1991; Winokur et al., 1995), social 
functioning (Kusznir et al., 2000; Tsai et al., 1997), educational level (Cardoso et al., 2008; Verduin 
et al., 2005) and quality of life (Cardoso et al., 2008; Mazza et al., 2009), the findings are also 
diverging.  
In addition to the conflicting findings, there are also methodological inconsistencies across 
the studies. Furthermore, effect sizes that may inform about the probable clinical impact are rarely 
reported. Thus, a critical review of the literature indicates that SUDs are probably not as 
consistently and globally associated with a more severe course and outcome as frequently 
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indicated in the literature, and further research is needed to clarify these issues. In the current 
study, we study potential differences in a wide range of clinical and functional characteristics 
between patients with and without excessive substance use. 
1.4 The onset and early phases of bipolar disorder 
There has been a growing focus on factors associated with the age- and mode of onset of BD. This 
increase in interest has several reasons including the growing general focus on early intervention 
strategies in severe mental illness, the possible increase in the prevalence of child- and adolescent 
BD as well as intensified efforts to identify risk factors for BD. One of the strongest predictors of a 
more severe illness course in BD, including increased psychiatric comorbidity, is an early onset 
(Schurhoff et al., 2000). Unraveling the factors associated with early onsets may be a path towards 
better understanding of disease mechanisms and prevention of severe outcomes. The present 
study will investigate factors associated with age at onset (AAO) in BD. 
1.4.1 Age at onset 
Several factors have been shown to be related to AAO in BD. Recent studies have found differences 
in AAO between research sites: Higher rates of childhood- or adolescent onset are more often 
reported from US studies (around 60%) than from European studies (around 30%) (Baldessarini et 
al., 2010; Post et al., 2008) including findings from our own study group (Larsson et al., 2010), even 
though there are exceptions (Baldessarini et al., 2010; Morken et al., 2009; Oedegaard et al., 2009). 
This variation in AAO has been attributed to factors ranging from differences in genetic loading to 
recruitment biases or methodological discrepancies such as the definition of illness onset (Larsson 
et al., 2010; Oedegaard et al., 2009; Post et al., 2008).  
There is extensive evidence that a family history of affective disorder is associated with 
earlier onsets (Leboyer et al., 2005; Rice et al., 1987; Strober, 1992). Most studies find a similar 
AAO for men and women (Hendrick et al., 2000), while some report earlier onsets in females (Lin et 
al., 2006; Suominen et al., 2009) and others earlier onsets in men with BD I (Baldessarini et al., 
2010). The subtypes of BD (BD I and II) appear to have a similar AAO (Judd et al., 2003); however, 
earlier onset in BD I was recently reported (Baldessarini et al., 2010), while a previous report from 
our study groups indicates that patients with BD II have the earliest onsets (Larsson et al., 2010).  
An early onset has also been associated with increased risk for substance use disorders, 
especially of illicit substances (Carlson et al., 2000; Carter et al., 2003; Ernst & Goldberg, 2004; 
Goldstein & Levitt, 2006; Lin et al., 2006; Perlis et al., 2004), and it has been hypothesized that early 
onset and drug abuse may share a common genetic basis (Lin et al., 2006). 
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1.4.2 Substance use as a risk factor for bipolar disorder 
There is growing evidence that several environmental factors may constitute risk factors for BD. 
One such candidate is childhood adversity, due to its high prevalence in BD and its association with 
both earlier onsets and more severe clinical expressions of the disorder (Etain et al., 2008; Garno et 
al., 2005; Leverich et al., 2002). In a study comparing several different types of childhood trauma, 
the earliest onset was found in patients that had experienced sexual adversity (Dienes et al., 2006). 
Furthermore, research has shown that life events such as loss-related events (death of spouse) or 
major life changes (moving, changing job) are over-represented in the period preceding the first 
affective episode in BD patients when compared to controls (Ambelas, 1987; Horesh & Iancu, 
2010). One study also showed that BD patients without a family history of affective disorder had 
more life events prior to illness onset compared to those with a family history (Johnson et al., 
2000), supporting the general observation that persons with low genetic vulnerability do not 
develop symptoms unless exposed to more severe environmental stressors.  Correspondingly, in 
the case of equal levels of genetic vulnerability, individuals experiencing more environmental 
stressors would have an earlier onset of illness and than individuals without. Furthermore, in 
individuals with low vulnerability, environmental triggers of sufficient severity may not elicit the 
disorder until at a later age and/or with a milder symptom expression than in persons with a high 
vulnerability. In support of this hypothesis, patients with life events preceding the onset of BD 
appear to have a later onset than in those without precipitating stressors (Johnson et al., 2000).  
 The latter finding is parallel to findings on BD and substance use disorders, which is 
considered as another possible risk factor. This line of research has investigated if there are 
differences in AAO depending on whether BD precedes or follows the SUD. A later onset has been 
found among patients with SUD preceding the BD (DelBello et al., 1999; Falk et al., 2008; Feinman 
& Dunner, 1996; Fossey et al., 2006; Strakowski et al., 1996; Strakowski et al., 2005; Strakowski et 
al., 2007). There is also evidence for a less severe clinical course (Goldstein & Levitt, 2006; 
Pacchiarotti et al., 2007; Strakowski et al., 2005; Winokur et al., 1995) and lower rates of family 
history of affective illness (DelBello et al., 1999) in BD that appears later than (secondary to) the 
SUD. Taken together, these findings have been interpreted as indications that substance abuse 
could precipitate the manifestation of BD in these individuals (DelBello et al., 1999; Strakowski et 
al., 2005; Winokur et al., 1995). This effect has been proposed for both alcohol (Winokur et al., 
1995), cannabis (Strakowski et al., 2007) and for any substance of abuse (Pacchiarotti et al., 2007). 
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Alcohol and cannabis as risk factors for BD 
Other indications that SUD is a potential risk factor for BD are the psychoactive substances’ 
tendency to mimic affective symptoms and/or interfere with neurobiological mechanisms also 
involved in the BD itself (Post et al., 1995). However, the pharmacological effects of substances of 
abuse are different. In line with this, alcohol and cannabis appear to have different effects on the 
course of an established BD. In a prospective study, cannabis use coincided with or preceded 
hypomanic or manic symptoms, while alcohol use coincided with or preceded depressive 
symptoms (Baethge et al., 2008). Mirroring the general population, the most commonly used 
substances in BD are alcohol and cannabis (Cassidy et al., 2001; McElroy et al., 2001). In another 
study from the TOP study group, with a sample partially overlapping the sample included in this 
thesis, the rates of alcohol use were found to be higher and the use of cannabis as the only drug 
more common in BD than in schizophrenia (Ringen et al., 2008), indicating that these substances 
may be of special relevance for BD. However, most clinical studies on BD have focused on either 
alcohol abuse alone or substance abuse in general. The present study aims to compare 
characteristics of patients using alcohol and patients using cannabis.  
During the recent years, indications have been growing from epidemiological studies that 
cannabis use is a risk factor for manic symptomatology. A prospective study found that cannabis 
use at baseline increased the risk for onset of manic symptoms (independently from psychotic 
symptoms) during a 3-year follow-up period with an OR of 2.7 (Henquet et al., 2006). Another 
study showed that cannabis use at baseline was associated with a fivefold increase in the risk of 
developing BD during a 3-year follow-up, with indications of a dose-response relationship (van Laar 
et al., 2007). Furthermore, in a recent cohort community study of adolescents, lifetime cannabis 
use (more than five times) increased the risk for onset of manic symptoms with an OR of 4.3 during 
an 8-year follow-up period (Tijssen et al., 2010). Thus, cannabis seems to be associated with an 
increased risk for developing both manic symptoms and the BD syndrome. 
Whether excessive alcohol use has a similar effect is less investigated. One epidemiological 
study investigated the sequencing of onsets of alcohol use disorders and mood disorders, and 
found that the alcohol use disorder preceded (hypo)mania in about half of the cases, and that the 
lag time until the onset of (hypo)mania was long (7.6 - 12.5 years). The authors described the 
possible relationship between alcohol use disorders and (hypo)mania as “temporally distal” (Falk et 
al., 2008). To my knowledge, no studies have investigated whether excessive use of cannabis and 
excessive use of alcohol are differently associated with AAO. Only one study has investigated the 
sequence of the onsets of cannabis abuse and BD and its relationship to AAO, showing that 
patients with a primary cannabis use disorder had a later onset compared to patients with no 
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cannabis use disorder or a secondary cannabis use disorder (Strakowski et al., 2007). This has not 
been replicated, and there is a need for further studies that simultaneously evaluate the 
associations between AAO and excessive alcohol or cannabis use. 
1.4.3 Early identification of bipolar disorder 
In the psychosis research field, evidence has accumulated over the last two decades indicating that 
early identification of psychotic symptoms is both possible and beneficial. Interventions on a 
population based level can reduce time from illness onset to help-seeking behavior and treatment, 
and this shortening of the duration of untreated psychosis appear to reduce the risk of a poor 
outcome (Melle et al., 2004). Considerable effort has also been made to identify and operationalize 
a “psychosis risk syndrome”. Successful although controversial attempts at treating such states to 
prevent or delay illness onset have been made (Correll et al., 2010). There has been much less 
focus on the early phases of BD, and this research field is thus behind the general psychosis 
research field regarding early identification and intervention. However, there is evidence that the 
risk of recurrence increases as a function of number of previous episodes in BD (Kessing & 
Andersen, 2005), as well as a growing documentation of substantial delays from the onset of 
affective episodes to the correct diagnosis (Berk et al., 2007). These issues have led to a call to 
extend the focus on early detection into the field of BD (Conus & McGorry, 2002; Salvadore et al., 
2008). Thus, recently attempts have been made at identifying prodromal symptoms of BD (Conus 
et al., 2008; Conus et al., 2010; Correll et al., 2007) and risk factors for transition from subthreshold 
affective symptoms to a full-blown BD (Tijssen et al., 2010). However, there is a great need for 
more basic knowledge concerning illness identification and treatment initiation in BD. 
1.4.4 The long road to adequate treatment in bipolar disorder 
A substantial proportion of persons with BD do not receive psychiatric treatment (Hirschfeld et al., 
2003; ten Have et al., 2002). Another problem is that many seem to experience delays from illness 
onset to correct diagnosis and/or initiation of adequate pharmacological treatment. In a study on 
patients with schizoaffective disorder or BD, median age at the first manic episode was 24 years, 
while the correct diagnosis was received at 30 years (Berk et al., 2007). In another study of BD 
patients, 44% had not received the correct diagnosis by the end of the first treatment period 
(Kessing, 2005), and in yet another study 34% experienced a delay of more than 10 years from first 
professional contact to correct diagnosis (Lish et al., 1994). Several studies have reported delays 
from first affective symptoms to start of adequate pharmacological treatment of approximately 9-
10 years (Altamura et al., 2009; Baethge et al., 2003; Leverich et al., 2002). However, identifying BD 
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and initiating adequate pharmacological treatment is only possible after the first (hypo)manic 
episode. Little is known regarding delay defined as the time from first (hypo)manic episode to the 
start of adequate pharmacological treatment, and what the risk factors for such delays are. The 
present study aims at investigating these and other aspects of treatment delay in BD. 
The consequences of long treatment delays 
While long durations of untreated illness is found to be clearly associated with a more severe 
course and outcome in schizophrenia (Marshall et al., 2005; Melle et al., 2008), it is more disputed 
whether treatment delays lead to a poorer outcome in BD. Some findings indicate that the 
response to treatment is not associated with long treatment delays (Baethge et al., 2003; 
Baldessarini et al., 2007). However, long durations of untreated illness was recently shown to be 
linked to elevated rates of suicidality, comorbid anxiety and substance use disorders in BD 
(Altamura et al., 2009), possibly due to the distress caused by untreated mood symptoms.  
What characterizes patients with long treatment delays? 
Increased knowledge about factors associated with long treatment delays can be used to form 
strategies for reducing such delays. Some patient characteristics that increase the risk for 
treatment delays have been identified. Female patients (Baldessarini et al., 2007; Kessing, 2005; 
Mantere et al., 2008), patients with early onset of the BD (Altamura et al., 2009; Baldessarini et al., 
2007; Berk et al., 2007; Goldberg & Ernst, 2002; Kessing, 2005; Larsson et al., 2009; Suominen et 
al., 2007) and patients with BD II rather than BD I disorder (Baldessarini et al., 2007; Mantere et al., 
2008) appear to have longer delays.  
Whether substance use increases the risk for treatment delay is not known. If substance 
use starts before the first BD episode, this may delay both diagnosis and onset of adequate 
treatment. The symptoms of substance intoxication, withdrawal and long term use may cause 
secondary affective symptoms that are indistinguishable from primary affective syndromes (Kleber 
et al., 2006) and thus delay the identification of BD (Albanese et al., 2006). After BD diagnosis, 
pharmacological treatment may be suboptimal, due to concern for interaction between substances 
and mood stabilizing agents (Albanese & Pies, 2004) and indications of poorer medication response 
(Tohen et al., 1998). There are few randomized controlled trials in patients with comorbid BD and 
SUD to guide the treatment choices. In line with this, a trend was found in one study that BD 
patients with alcohol use disorders had longer delays from onset of affective symptoms to 
treatment with mood-stabilizers (Goldberg & Ernst, 2002).  
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On the other hand, BD patients with more severe clinical presentations are more likely to 
seek help rapidly (ten Have et al., 2002) and also receive treatment faster (Baethge et al., 2003; 
Baldessarini et al., 2003; Goldberg & Ernst, 2002; Mantere et al., 2008) than patients with less 
severe symptomatology. In general, the odds for patients with co-occurring mental and substance 
use disorders using health services are higher than for patients with a single disorder (Jacobi et al., 
2004; Regier et al., 1993; Urbanoski et al., 2007; Wu et al., 1999). Taken together, there are 
indications that the presence of comorbid SUD may be associated with both longer and shorter 
treatment delays in BD patients. These discrepancies may also be related to whether the substance 
abuse appears before or after the onset of the first BD episode. If the first BD episode starts before 
the substance abuse, treatment delay may increase the risk for substance use as self-medication of 
mood symptoms.  
Self-medication as a possible consequence of treatment delay 
The self medication hypothesis originally proposed by Khantzian in 1985 postulated that specific 
substances are used in order to alleviate particular painful affects (Khantzian, 1985). In a later 
reconsideration of the hypothesis, the author also claims that self-medication occurs because of 
“difficulties in regulating affects, self-esteem, relationships and self care” (Khantzian, 1997), but 
maintained the notion that a drug may be especially appealing to an individual due to his/her 
personality organization and specific psychological suffering. There is little or no evidence that 
specific substances are associated with specific psychiatric disorders, nor is it clear that patients 
with BD selectively use substances to match their affective phase. Some findings, however, indicate 
that the latter may be the case. In a prospective study, alcohol use was found to be more prevalent 
during depressive episodes and cannabis use more prevalent during manic episodes (Baethge et al., 
2008).  
Another model incorporating the idea of self-medication is the “stress-coping model” of 
addiction, which suggests that substances are used both to reduce negative affect and increase 
positive affect (Shiffman & Wills, 1985). In the realms of BD, where affective instability is the 
cornerstone, this model seems to have high face validity. Closely related to this hypothesis is the 
“alleviation of dysphoria” model. This suggests that humans use substances to ease dysphoric 
mood, and because individuals with severe mental disorders are especially prone to dysphoric 
experiences they are also more prone to use psychoactive substances (Mueser et al., 1998). There 
are several studies supporting the notion that patients with BD use substances to alleviate mood 
symptoms. In a clinical study, patients with BD and SUD scored higher on the self-medication items 
of a self-report measure compared to BD patients without SUD (Bizzarri et al., 2007). In an 
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epidemiological study, 41% of the patients with BD reported to have used substances to relieve 
mood symptoms in one or more affective episodes (Bolton et al., 2009). In a qualitative study 
patients reported that they used substances both to cope with depression and to alleviate 
symptoms of elation (Healey et al., 2009).  
For patients experiencing long treatment delays, the likelihood of developing excessive 
substance use may increase as a consequence of an escalating need of symptom alleviation. 
Whether patients without initial excessive substance use that experience long treatment delays 
have an increased risk of developing excessive substance use has to my knowledge not yet been 
investigated.  
1.5 Synopsis and introduction to aims 
Individuals with BD often abuse psychoactive substances. To what extent BD patients without SUDs 
use substances (excessively or occasionally), is sparsely investigated. Furthermore, although the 
rates of SUDs among patients with BD are generally high they also vary widely. As substance use 
varies across cultures and geographical areas, the prevalence of substance use in a BD population 
should be compared to the prevalence in the general population of the same geographical area.  
To what degree and in which outcome areas substance abuse and -dependence have a 
negative impact on the BD are research questions that have given diverging answers so far. Thus, 
further research conducted on well characterized and representative patient samples is needed, 
both to clarify which characteristics are associated with excessive substance use and how strong 
these associations are. 
During the recent years, there has been increasing focus on the age at onset of BD. 
Variation in age at onset has been associated with several factors, including substance abuse. 
However, the relationship between age at onset, type of substance use and sequencing of the 
onsets of BD and excessive substance use calls for further investigation. 
Research has shown that the delay between the onset of BD and a correct diagnosis and 
adequate treatment is long. How this delay is related to excessive substance use is sparsely 
investigated. When excessive substance use precedes the onset of the BD, it may both delay and 
expedite treatment initiation. When patients experience long delays from onset of the BD until 
treatment initiation, this may also increase the risk of excessive substance use as an attempt to 
self-medicate increasing symptoms. 
The focus of this thesis is the relationship between excessive substances use and central 
aspects of BD; the development or onset of the disorder, the clinical and functional characteristics, 
and the initiation of adequate treatment.  
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2 AIMS OF THE THESIS 
The main objective of this thesis was to gain more knowledge on the relationship between 
excessive substance use and BD, with special focus on age at onset, treatment delay and outcome. 
To obtain this, the following research questions were addressed in the individual papers: 
Paper I:  
1) Is the rate of lifetime use of illicit substances higher in the patient sample than in the reference 
population?  
2) Do patients with and without excessive substance use, defined as substance use disorders 
and/or excessive use, differ on clinical and functional characteristics, in terms of disease course 
variables, current symptom levels and functioning?   
Paper II:  
3) Does the age at onset of the bipolar disorder differ between patients with excessive alcohol use, 
excessive cannabis use and patients using neither substance?  
4) Does type of excessive substance use (alcohol, cannabis) and sequencing (of the onset of 
excessive substance use and the bipolar disorder) independently predict age at onset after 
adjusting for possible confounders?  
Paper III:  
5) What are the predictors of treatment delay, and is there a difference in primary BD (no excessive 
substance use preceding the first BD episode) and secondary BD (excessive substance use 
preceding the onset of the first BD episode)?   
6) Within the primary BD group, do long treatment delays increase the risk of later excessive 
substance use?  
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3 MATERIAL AND METHODS 
3.1 Setting 
The current study is part of The Thematically Organized Psychosis (TOP) study. This is a large 
collaboration between the University of Oslo, Oslo University Hospital (formerly Ullevål University 
Hospital, “Rikshospitalet” and Aker University Hospital), Lovisenberg - Diakonhjemmet Hospital, 
and two large hospitals outside of Oslo. The project has a translational approach, aiming at gaining 
more knowledge on clinical, biological and environmental aspects of BD, schizophrenia and related 
psychiatric disorders. Patient inclusion started in October 2002 and is still ongoing. The TOP study 
aims at recruiting all patients within the relevant diagnostic groups that are being treated in public 
psychiatric services. To aspire to do this, the recruiting personnel collaborates closely with the 
clinical staff in the psychiatric units. The current study is cross-sectional and naturalistic. The 
project is approved by the Regional Committee for Medical Research Ethics as well as the 
Norwegian Data Inspectorate, and the data file received an Audit Certificate from the Center for 
Clinical Research at Ullevål University Hospital in 2007.  
3.2 Material 
Patients included in the current study were recruited from the psychiatric units (in- and outpatient) 
of the three major hospitals in Oslo from 2003 - 2008. Patients with a DSM-IV BD I, II or NOS 
diagnosis were recruited. Participants were excluded if they had a history of moderate/severe head 
injury, neurological disorder, developmental delays, an age outside of 18–65 years, or if they did 
not speak a Scandinavian language. Patients were referred to the project by their treating clinician 
after an evaluation of their eligibility and ability to give informed consent. The clinical interviews 
were conducted by research fellows who were trained clinicians (M.D.s or clinical psychologists). 
Informed consent was signed before the interview started. In some cases, the inclusion process 
was started while the patient was hospitalized. However, to ensure that patients were 
symptomatically stable and able to give informed consent, most of the assessments took place in 
out-patient clinics.  
The patient sample of paper I consists of 125 patients included from 2003 to 2007. An 
additional 26 patients were included until August 2008 and added to the original sample, 
comprising the patient sample of paper II and III.  In the total group of 151 patients, 88 (58.3%) had 
BD I, 57 (37.7%) BD II and 6 (4%) BD NOS. The 6 BD NOS patients were for the data analyses 
recoded as either BD I or BD II depending on the presence of mania or hypomania in their illness 
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history. Other sociodemographic and clinical characteristics of this sample are presented in Table 2. 
The 26 patients that were lastly added did not differ significantly from the original sample on any 
relevant measures. 
 
Table 2. Total sample sociodemographic and clinical characteristics. 
In paper I, a sample from the general population collected by the Norwegian Institute for Alcohol 
and Drug Research (SIRUS) was used as a reference group. SIRUS regularly conducts surveys of the 
Norwegian population’s consumption of illicit substances by personal interviews via standardized 
questionnaires. Sampling strategies are used to ensure random sampling and thus representativity. 
In the present study, SIRUS data from Oslo in 2004 was used (Horverak & Bye, 2007). For matching 
purposes, participants aged 18-65 were selected, leaving a representative sample of 327 subjects. 
Total sample 
  N=151# 
Gender, female, n (%) 92 (60.9) 
Age, years, mean (SD) 35.9 (11.8) 
Ethnicity, Caucasian, n (%) 139 (92.1) 
Marital status, married/living as married, n (%) 49 (32.5) 
Years of education, mean (SD) 14.5 (3.0) 
Age at first affective episode, years, mean (SD) 22.7 (9.3) 
Duration of illness, years, median (IQR) 11 (15) 
Lifetime use of illicit drugs, n (%) 100 (66.2) 
Substance use disorder*, n (%) 47 (31.1) 
Excessive substance use*, n (%) 19 (12.6) 
Age at onset of SUD or excessive substance use, years, mean (%) 23.5 (10.1) 
Hospitalized (lifetime), n (%)¤ 103 (68.2) 
No. of hospitalizations, median (IQR) 1 (3) 
Lifetime psychotic symptoms, n (%) 71 (47) 
Lifetime adequate pharmacological treatment, n (%) 108 (71.5) 
GAF S, mean (SD) 56.5 (10.9) 
GAF F, mean (SD) 53.6 (11.7) 
IDS-C, median (IQR) 14 (18) 
SUD=Substance use disorder. GAF S=Global Assessment of Functioning Scale, symptom 
subscale. GAF F=Global Assessment of Functioning Scale, Functioning subscale. IDS-
C=Inventory of Depressive Symptoms, Clinician rated. 
#in which the original sample of 125 patients is included 
*Lifetime, of at least one substance. Patients with both SUD and excessive use are only coded with SUD.  
¤3 missing 
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3.3 Methods 
3.3.1 Diagnostic assessment 
Diagnoses were established using the Structured Clinical Interview (SCID) for DSM-IV, modules A-E 
(First et al., 1995). All interviewers were trained based on the training program at UCLA (CA, USA) 
and participated in regular diagnostic consensus meetings. A good inter-rater reliability based on 
the UCLA training procedure was achieved with an overall kappa score of 0.77 (95% CI: 0.60-0.94). 
To assess reliability for actual study interviews a stratified random sample was drawn, consisting of 
cases from most of the assessment staff members. Anonymous vignettes describing symptoms and 
development of the illness were then rated by two experts blind to the study ratings. For the 28 
vignettes the overall agreement for the nine DSM-IV diagnostic categories was 82% and the overall 
Kappa again 0.77 (95% CI: 0.60-0.94). 
3.3.2 Assessment of sociodemographic characteristics, symptoms and illness course  
Data were collected regarding age, gender, ethnicity, marital status, education, occupational 
status, family history of psychiatric disorders including substance abuse, history of suicide 
attempts, - psychosis, - psychiatric hospitalizations and psychopharmacological medication, age at 
onset of affective episodes, and age at first contact with specialized psychiatric care. This 
information was cross-checked with medical charts and information from interviews with close 
family members if relevant. Patients were considered to have had a lifetime psychosis if they had 
one or more SCID-verified psychotic episodes. A family history of depression, BD, schizophrenia, 
and other psychotic disorders among first degree relatives (i.e. mother, father, brothers and 
sisters) was obtained through patient interviews. Patients having a minimum of one first-degree 
relative with one or more psychiatric disorders were considered to have a family history. A family 
history of psychotic disorders other than BD was considered since several recent studies have 
shown common heritability for BD and schizophrenia (Craddock et al., 2009; Lichtenstein et al., 
2009). 
Depressive symptoms were assessed with the Inventory of Depressive Symptomatology 
(IDS-C) (Rush et al., 1996), (hypo)manic symptoms with the Young Mania Rating Scale (YMRS) 
(Young et al., 1978), general non-psychotic symptoms by the Positive and Negative Syndrome Scale 
(PANSS) (Kay et al., 1987), and current functioning by the Global Assessment of Functioning Scale 
(GAF) (Endicott et al., 1976), split version (Pedersen et al., 2007). The Medication Adherence Rating 
Scale (MARS) (Thompson et al., 2000) was used to measure compliance to medication. Increasing 
GAF scores signify fewer symptoms or better functioning, while for the remaining symptom scales, 
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higher scores signify more symptoms. The reliability for the PANSS general subscale was good, with 
an intraclass correlation coefficient (ICC) of 0.73 (95% CI: 0.54-0.90). The ICC was 0.86 (95% CI: 
0.77-0.92) for GAF-S and 0.86 (95% CI: 0.77-0.92) for GAF-F. 
3.3.3 Excessive substance use assessment and definitions 
Substance use disorders were diagnosed through the SCID E-module. Each patient also reported 
lifetime substance use (daily, weekly, monthly, or occasional/no use) for all substances for the 
following life periods: 11-15 years, 16-20 years, 21-27 years, 28-44 years, 45-60 years, and 60+ 
years.  (Appendix, Table 2). The intervals were based on the possibility of different use patterns and 
differences in the pathophysiological influence of substances across different life periods. The 
lifetime substance use evaluation is administered as an interview, where the scores are based on 
the clinician’s evaluation of the patients’ reports. When a specific use period did not correspond 
with a defined period, it was coded in the period with the greatest overlap. The frequency coded 
was also the average or predominant frequency within a period; “weekly” could be less than 
weekly for a sub-period if it was also equivalently more than weekly within the same period. 
Predominantly daily use of alcohol and predominantly weekly use of a non-alcoholic substance 
throughout at least one of the life periods (i.e. minimum 4 years) were considered excessive.  
Structured interviews about the consumption of substances the last 6 months were also 
conducted; alcohol use was assessed by number of units and illicit substances by number of 
incidents. Different non-alcoholic substances were asked for specifically and the use was quantified 
by totaling the number of incidents recalled. When units or incidents were too frequent for precise 
recall, effort was put into identifying typical periods of mean weekly use and adding up by number 
of weeks for that period. Data on incidents of use past 6 months were pooled for all non-alcoholic 
substances, and specific incidents for each drug were not recorded unless only one type of drug 
had been used. There were no statistically significant differences regarding the number of units of 
alcohol or number of incidents of use of non-alcoholic substances consumed the last 6 months 
between patients fulfilling SUD criteria and patients with excessive use (Table 4). But these two 
groups combined differed significantly from the group with neither SUD nor excessive substance 
use regarding use of alcohol and illicit substances the last 6 months (Table 5). Thus, in the current 
study, excessive substance use was defined as substance use either fulfilling lifetime SUD or 
excessive use criteria. Age at onset of excessive substance use was deemed to be either 1) the age 
when DSM-IV SUD criteria were first met, or 2) the age when the patient started daily use of 
alcohol or weekly use of a non-alcoholic substance(s). 
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 IQR=Interquartile range. U=Mann Whitney U-test. 
 
Excessive use of alcohol versus cannabis 
 In paper II, patients with excessive alcohol use, excessive cannabis use and patients without such 
excessive use were compared. Twenty-eight patients (19%) had excessive alcohol use, 24 patients 
(16%) had excessive cannabis use, and 11 patients (7%) used both substances. Patients who used 
both were similar to the patients who used cannabis only and not to the patients who used alcohol 
only for all relevant clinical and sociodemographic characteristics, and were therefore grouped 
together with the cannabis-only patients in the bivariate analyses for research question 1.  But to 
further ensure that the differences between the alcohol and cannabis groups were not due to the 
characteristics of the patients using both alcohol and cannabis, follow-up analyses were conducted 
excluding these patients. These analyses did not indicate any changes in the group wise differences 
for age, AAO and age at onset of excessive substance use, or for the proportion with BD I or a 
family history of affective/psychotic disorder compared to the original analyses. The difference in 
the proportion with excessive use of other substances was, however, no longer significant (18% vs. 
25%, χ2=0.40, p=0.53) implying that excessive polysubstance use was a characteristic of the 
excluded group. Among the 88 patients with neither excessive alcohol nor cannabis use, three 
patients (3%) had excessive use of other substances. These 88 patients are subsequently referred 
to as non-users. 
Table 4. Consumption of alcohol and illicit drugs the last 6 months for patients with substance 
use disorders versus excessive use. 
  Patients with SUD Patients with excessive use Test statistics 
Units of alcohol, median (IQR) 75 (399) 130 (398) U=313.00, p=0.55 
Incidences of illicit drug use, median (IQR) 0 (4) 0 (12.5) U=290.00, p=0.65 
SUD=Substance use disorder. 
Table 5. Consumption of alcohol and illicit drugs the last 6 months for patients with substance 
use disorders or excessive use versus patients with neither. 
  
Patients with 
SUD or 
excessive use 
Patients 
with 
neither Test statistics 
Units of alcohol, median (IQR) 121 (394) 36 (106) U=1365, p=0.037 
Incidences of illicit drug use, median(IQR) 0 (5) 0 (0) U=1448.5, p=0.001 
SUD=Substance use disorder.  
IQR=Interquartile range. U=Mann Whitney U-test 
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3.3.4  Temporal sequencing 
In paper II, AAO was defined as the age when the first SCID-verified affective episode began. In 
paper II and III the patients were divided into two subgroups determined by the presence or 
absence of excessive substance use preceding the first affective episode: primary BD were patients 
with no excessive substance use preceding the first affective episode, and secondary BD were 
patients with onset of the first affective episode after the onset of excessive substance use. This 
dichotomous variable is subsequently referred to as the sequencing of onsets. The small group of 
patients (n=6) with onsets of both within the same year was categorized as secondary BD. This was 
done because excessive substance use to a greater degree than BD has a gradual rather than an 
abrupt onset. Since all patients in this study eventually were diagnosed with BD, affective episodes 
associated with substance use in patients with no previous BD episode were used as markers for 
the AAO. Using these criteria, 117 patients had primary BD (77%) and 34 (23%) had secondary BD. 
Patients with primary BD could develop excessive substance use after the onset of BD, and data 
showed that 32 patients (21% of all patients) subsequently did. 
3.3.5 Treatment delay 
Several definitions have been used to define the onset of BD: First affective symptoms (Goldberg & 
Ernst, 2002; Morken et al., 2009; Post et al., 2008), first affective episode according to diagnostic 
criteria (Larsson et al., 2009; Oedegaard et al., 2009; Suominen et al., 2007), first medical contact 
because of the BD (Baethge et al., 2003) and time of first psychiatric intervention (Baldessarini et 
al., 1999; Baldessarini et al., 2003). Also, at least two different definitions of treatment start have 
been used: First contact with psychiatric care irrespective of mood disorder diagnosis (Suominen et 
al., 2007) and first treatment with a mood-stabilizer (Goldberg & Ernst, 2002). There is thus no 
consensus in the field on the definition of BD treatment delay that parallels the concept of 
“duration of untreated psychosis” used in studies of psychotic disorders (Melle et al., 2004). For the 
purpose of the health service focus of research question 5 (paper III), the start-point was defined as 
the first time it was possible to give the BD diagnosis – i.e. the onset of the first SCID-verified 
elevated episode (hypomanic, manic or mixed). For the purpose of the clinical focus of research 
question 6 (paper III), the onset of the first SCID verified affective episode regardless of polarity 
was defined as the start-point. The end-point was for both research questions defined as age at 
first mood-stabilizing or antipsychotic medication, defined as appropriate dosages for at least 6 
weeks in line with available treatment guidelines for BD (Goodwin, 2009; Grunze et al., 2004). The 
treatment delay variable was highly skewed and could not be transformed into a normal 
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distribution by any form of transformation and was thus dichotomized into short and long delay by 
the median value of 2 years (short delay ≤2 years, long delay >2 years). 
3.4 Statistical analyses 
All analyses were done using the Statistical Package for the Social Sciences (SPSS) version 16.0 (Inc., 
Chicago, IL, USA). Statistical significance was determined using the .05 level and 2-tailed tests of 
significance. Chi-square tests and Fisher’s exact tests were used when investigating group 
differences on categorical data. Group differences in independent samples were explored with 
Student’s t-tests and ANOVAs (with Tukey’s post-hoc tests) on normally distributed continuous 
variables and Mann Whitney U-tests and Kruskal Wallis tests for variables with skewed 
distributions. The distribution of skewed variables is presented through medians and interquartile 
ranges (IQR). Bivariate associations between continuous dependent and independent variables 
were assessed with Pearson correlations when variables were normally distributed and Spearman 
rank correlations when variables were skewed. The Kaplan-Meier Survival Analysis was used for 
comparing groups on time in remission. Binary logistic regression analyses were used to investigate 
the relationship between a dichotomous dependent variable and multiple independent variables. 
Hierarchical multiple regression analyses were used to investigate the relationship between one 
continuous dependent variable and multiple independent variables. The two-way ANOVA was used 
to investigate possible interactions between variables. Possible confounders were chosen on the 
basis of associations found in bivariate analyses and findings from earlier studies. For concrete 
details on statistical analyses in each of the substudies, the reader is referred to the papers. 
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4 RESULTS AND SUMMARY OF PAPERS 
Paper I: Excessive substance use in bipolar disorder is associated with 
functioning rather than clinical characteristics, a descriptive study 
Background: There is a strong association between BD and SUD. The clinical and functional 
correlates of SUD in BD are still unclear and little is known about the role of excessive substance 
use that does not meet SUD criteria. Thus, the aims of the current study were to investigate 
lifetime rates of illicit substance use in BD relative to the normal population and if there are 
differences in clinical and functional features between BD patients with and without excessive 
substance use.  
Methods: 125 consecutively recruited BD in- and outpatients from the Oslo University Hospitals 
and 327 persons randomly drawn from the population in Oslo, Norway participated.  Clinical and 
functional variables were assessed. Excessive substance use was defined as DSM-IV SUD and/or 
excessive use according to predefined criteria. 
Results: The rate of lifetime illicit substance use was significantly higher among patients compared 
to the reference population (OR=3.03, CI=1.9-4.8, p<.001). Patients with excessive substance use 
(45% of total) had poorer educational level, occupational status, GAF-scores and medication 
compliance, with a trend towards higher suicidality rates, compared to patients without. There 
were no significant group differences in current symptom levels or disease course between groups.   
Conclusion: The percentage of patients with BD that had tried illicit substances was significantly 
higher than in the normal population. BD patients with excessive substance use clearly have 
impaired functioning, but not a worse course of illness compared to patients without excessive 
substance use. An assessment of substance use beyond SUD criteria in BD is clinically relevant.  
Paper II: Excessive cannabis use is associated with earlier age at onset 
compared to excessive alcohol use in bipolar disorder 
Background: Several factors appear to be associated with variation in age at onset in BD, substance 
use being one. How different substance types and differences in the temporal relationship 
between the onset of BD and the onset of substance use are related to age at onset is unclear. The 
aim of the study was to investigate which factors are associated with age at onset in bipolar 
disorder with a specific focus on excessive alcohol and cannabis use, and the sequence of the 
onsets of excessive substance use and bipolar disorder.  
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Methods: We investigated a naturalistic sample of 151 patients with bipolar I and II disorder 
receiving psychiatric treatment. Whether the presence of excessive substance use prior to bipolar 
disorder onset or the type of substance used (alcohol or cannabis) was associated with differences 
in age at onset was investigated using hierarchical, multiple linear regression analyses, adjusting for 
potential confounders.  
Results: Patients with excessive alcohol use had a significantly later onset compared to patients 
with excessive cannabis use. Excessive general substance use prior to bipolar disorder onset was 
associated with a later onset. However, excessive cannabis use was associated with an earlier onset 
whether it preceded or followed bipolar disorder onset, also after adjusting for possible 
confounders. Excessive use of alcohol or other substances was not independently associated with 
age at onset in multivariate analyses.  
Conclusions: Alcohol use was associated with a later onset compared to cannabis use, suggesting 
different relationships to the onset of bipolar disorder. Lifetime use of cannabis was associated 
with an earlier onset, independent of the sequence of onsets. This indicates that an early onset 
may increase the risk of cannabis use and that cannabis use may trigger bipolar disorder in 
vulnerable individuals. 
Paper III: Treatment delay and excessive substance use in bipolar 
disorder 
Background: The delay between illness onset and adequate pharmacological treatment in BD is 
often long. How treatment delay is related to excessive substance use has been sparsely 
investigated. The objective of the present study was to investigate whether excessive substance 
use before illness onset is associated with increased or reduced treatment delay, and whether long 
treatment delays are associated with increased risk for subsequent excessive substance use. 
Methods: 151 BD I and II patients were consecutively recruited from in- and outpatient psychiatric 
units, and categorized as primary or secondary BD (with or without antecedent excessive substance 
use). Predictors of treatment delay among all patients, and predictors of subsequent excessive 
substance use among primary BD patients, were investigated with logistic regression analyses.  
Results: The median treatment delay was 2.0 years (IQR 14.0). The risk of a long treatment delay 
(>2 years from first elevated episode to adequate pharmacological treatment) was increased in 
patients with BD II disorder, no lifetime psychosis, a higher age at first contact with specialized 
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psychiatric services, primary BD and excessive substance use. In primary BD, the risk for developing 
excessive substance use was increased in males, in patients with shorter education and longer 
treatment delays. 
Conclusion: Patients with antecedent excessive substance use had reduced risk of long treatment 
delays. The risk of developing excessive substance use after BD onset increased with longer 
treatment delays. 
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5 DISCUSSION 
5.1 Methodological issues  
5.1.1 Sample representativity 
The current study is based on a sample recruited in a publicly funded, catchment-area organized 
health care system with no alternative treatment facilities (e.g. private clinics). The cost carried by 
each patient receiving outpatient health care and/or prescribed drugs is limited to a fixed amount 
(NOK 1840 (EUR 228) per year), and access to in-patient care is free. In areas where health service 
utilization and access are partly governed by external factors such as cultural preferences (e.g. 
treatment in a university clinic is considered the most up-to-date) or lack of public funding (e.g. the 
only way to receive treatment is to participate in research), there is a risk of selecting patients that 
are not representative of the total population of treatment-seeking individuals. Some of the 
leading and most influential studies on BD may be biased due to such preselection. In the sample of 
the present study, the risk of preselection is minimal, since patients participating in health care 
based research in Norway are likely to spread across all socio-economic and -cultural categories. 
The TOP study sample is also examined within a time interval of approximately five years, assuring 
concordance in time for variables susceptible for rapid changes within any given society (such as 
illegal drug use).  
The aim was to include all eligible patients in treatment for the relevant diagnoses. Patients 
were recruited from both in- and outpatient units including substance abuse clinics. However, 
some potential biases need to be considered: Patient inclusions were based on referrals from their 
treating clinicians, and thus depended on the clinicians’ understanding and good-will towards the 
aim to include all eligible patients. To ensure this, the TOP interviewers were based in one or two 
clinics, together covering all sites. They attended regular meetings to inform new staff members, 
remind all that patient inclusion was ongoing, and discuss possible cases. Clinicians may however 
have been skeptical towards research in general or “protective” on behalf of patients they 
considered fragile or severely ill. The impression was however that the possibility to receive a 
written report from state-of-the-art assessments outweighed potential skepticism. Furthermore, 
since the assessment period ran across several years, most patients were likely to be targeted in 
stable phases of their illness. Some clinicians may also have lacked the experience needed to 
identify the right patients. Research has documented that BD is often misdiagnosed (Hirschfeld et 
al., 2003). The impression was however that the diagnostic service offered by the TOP interviewers 
often was used as a second opinion in complicated or potential cases. Thus, in our opinion there 
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are few clear indications that the referral procedures have caused significant biases. We however 
do not have any information on the number or characteristics of eligible patients that were not 
referred due to the reliance on clinicians to do the initial screening. 
One may also question whether the sample could be biased due to patients declining to 
participate after referral. Patients with severe forms of BD such as rapid cycling or chronic 
depressive courses may have declined more often than patients with less severe symptomatology. 
However, as described above, patients were asked again when symptom load was attenuated. 
Another possible excluding factor may have been that patients that had never experienced 
psychosis would be reluctant to participate in a project named “Thematically Organized Psychosis 
Study”. However, the project name was known by most patients in its abbreviated form “TOP”, and 
patients with non-psychotic BD would be informed by both their clinician and the interviewer that 
they were eligible. The proportion with psychotic symptoms in the current study was 47% (Table 2), 
which is similar to findings from other clinical studies on BD (Mantere et al., 2004; Mitchell et al., 
2009). Thus, there does not seem to be a bias towards psychotic BD in the present material.  
Furthermore, some patients may have perceived the assessment as too extensive. In such 
cases, patients were encouraged to participate in as many assessments as they wanted rather that 
to decline. The vast majority of cases participated in all baseline assessments, indicating that the 
total burden was regarded as acceptable by most patients. As in all research projects, a bias 
towards patients with a positive attitude towards research could be assumed. This is however likely 
to be related rather to the fact that some patients are more easily recruited to research than 
others, than to the specific design of the current study. Information regarding patients declining to 
participate in the study could not be accessed due to the person data security act.  
In order to investigate the representativity of the patients included in the TOP Study, data 
were compared with accessible variables from the Ullevål 600 Health Care Study. This is a survey 
conducted during the first years of recruitment in the TOP Study on all patients from the 
Department of Psychiatry at the former Ullevål University Hospital (constituting the largest and 
most heterogeneous health care sector in Oslo), comprising a total of 1002 subjects with psychoses 
and severe BD. These comparisons show that the TOP patients are representative for the clinical 
population as a whole on variables such as socioeconomic status, level of education, and substance 
use. The mean age of the current study’s sample was slightly lower compared to the Ullevål 600 
Study: 35.9 (11.8) versus 39.2 (12.8) years.  
The mean age at onset of the BD in the current sample was 22.7 years, and age at onset 
and age at assessment were moderately correlated (r=0.52). Thus, this is a fairly young sample with 
relatively short illness duration, i.e. consisting of few chronic patients. Twenty-eight percent of the 
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patients had not yet received adequate pharmacological treatment, suggesting that they were 
either recently referred to treatment, or had a relatively low level of symptoms. The majority of 
patients were also recruited from out-patient clinics.  
The patient sample of the current study is not an epidemiological sample, which probably 
would have included more cases with very benign forms of BD and cases that chose not to have 
contact with treatment services or fail to comply with specialized treatment (e.g. attending 
appointments). There are however many indications that the sample of the current study consists 
of patients representative of an unselected treatment-receiving population of patients with BD. 
Due to the varying quality of epidemiological studies on the prevalence and incidence of BD, it is 
difficult to estimate how close the number of patients included in the present study is to the actual 
number of individuals with BD in the catchment area covered. 
5.1.2 Reliability and validity of assessments 
The instruments employed to assess diagnoses, symptoms, and level of functioning in the TOP 
Study are widely recognized and utilized in clinical psychiatric research. It is well documented that 
the SCID-I interview in general may yield highly reliable diagnoses (Segal et al., 1994), and it is 
considered to be the gold standard of diagnostic assessment. The Inventory of Depressive 
Symptoms, Clinician Rated (IDS-C) has a more complete item coverage compared to other 
frequently used measures of depressive symptomatology, and has satisfactory psychometric 
properties (Rush et al., 1996). The Young Mania Rating Scale (YMRS) with its good psychometric 
properties (Young et al., 1978) is often regarded as the gold standard for assessment of manic 
symptomatology (Poolsup et al., 1999). The Positive and Negative Syndrome Scale (PANSS) is 
developed for schizophrenia, but has been used in previous studies on BD without encountering 
significant validity problems (Daneluzzo et al., 2002). The GAF Scale constitutes the axis V of the 
present DSM-IV diagnostic system, and has achieved worldwide status as a primary instrument for 
assessing change in psychiatric symptoms and functioning. Although its reliability in clinical settings 
has been questioned, especially the split version, it has proven highly satisfactory in research 
settings (Pedersen et al., 2007; Vatnaland et al., 2007). 
Reliable ratings in the use of all clinical measures in the TOP Study were ensured in several 
ways. Firstly, all interviewers were experienced clinicians, and went through standardized 
education and training on all clinical instruments. The interviewers had biweekly supervision 
including reviews of ongoing clinical interviews, and participated in monthly diagnostic supervision 
meetings led by a senior clinician/scientist. Furthermore, inter-rater reliability tests were 
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conducted for the SCID, PANSS and GAF assessments and showed very good to excellent results 
(for details, see methods section).  
Retrospective gathering of data on the development of symptoms and drug use implies the 
possibility of recall bias. Information on illness history was therefore cross-checked with case files, 
and with family members if it appeared conflicting or deficient, which could be the case e.g. when 
illness history was long or insight in symptoms low. Self-report of substance use in patients with BD 
has previously been shown to have a high degree of validity, especially when urine samples are also 
collected with the patients’ prior knowledge (Weiss et al., 1998). This was the case in the current 
study, and urine samples corresponded well (in 90% of the cases) with patients’ own reports of 
consumption of non-alcoholic substances in the previous weeks (Ringen et al., 2007). To further 
ensure that substance use was not under-reported, we gave patients the opportunity to have such 
information excluded from the reports sent to the treating clinician to avoid potential negative 
consequences. A few patients chose to report drug use only on this precondition. The lifetime 
substance use measure used to assess excessive substance use in the present study (Appendix, 
Table 2) was designed by collaborators in the TOP Study, and has not been tested for validity and 
reliability. However, it is a straight-forward measure of frequency of substance use with high face 
validity and relatively little room for interpretation (see methods section). SIRUS used phone 
interviews to collect information on drug use, which have disclosure rates similar to in-person-
interviews and paper-and-pencil questionnaires, and the advantage of higher participation rates 
(Rosenbaum et al., 2006).  
Using patients’ reports to record family history of psychiatric diagnoses has some limitations, 
including relatively poor sensitivity and specificity (Roy et al., 1996). A more reliable method would 
have been conducting diagnostic interviews with all first degree relatives. However, compared to 
other Norwegian cities, Oslo has a high proportion of inhabitants that have relocated from other 
cities, which would make such interviews very resource-intensive. Furthermore, a meta analysis of 
the psychometric properties of patient’s reports of family history yielded relatively high reliability 
and validity for schizophrenia, mania and substance abuse (as opposed to for anxiety, depression 
and personality disorders) (Hardt & Franke, 2007). These disorders constitute the majority of the 
disorders of interest in the current study.   
5.2 Ethical considerations 
Although the project’s ethical aspects are officially approved, and all patients participating in the 
study signed informed consent, some ethical issues should be addressed. In patients with 
psychiatric symptoms that may interfere with reality testing, the concept of informed consent 
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involves special challenges. Therefore, the patient’s psychiatric condition was thoroughly evaluated 
by their treating clinician and the research fellow in collaboration before the patient was asked to 
participate. The way the information about the study was communicated was individually adjusted; 
some patients needed to have the information on more than one occasion before assessments 
started. Patients were also explicitly told that they could, at any time, decline from the study, and 
that this would not have any consequences for their treatment in the clinic. The collaboration with 
the clinicians also ensured that participation in the study did not interfere with the treatment.  
Parts of the patient data on which this study is based, is highly personal and sensitive and 
thus emotionally loaded. In addition to working to obtain an empathetic atmosphere during the 
interviews, the assessments were often broken up into several sessions on different days. The 
interviews were carried out at either at the clinic or in the research offices, according to the 
preference of the patient. In addition to the clinical interviews, blood and urine sampling, somatic-, 
neuropsychological- and brain imaging- assessments were carried out. The total load on each 
participant may be compared to a thorough clinical evaluation. When needed, patients were 
offered taxi transportation for the appointments.  
When assessments were completed, reports from the neuropsychological testing and the 
clinical interview were written and sent to the treating clinician with the patients consent. Patients 
were also offered an appointment with the interviewer with the treating clinician present where 
the information from the reports was presented orally and discussed. The general impression was 
that both the written reports and the feed-back appointments were highly appreciated as useful by 
both the clinician and the patient. 
5.3 Discussion of main results 
5.3.1 The prevalence of lifetime illicit substance use in bipolar disorder  
Sixty-five percent of the patient sample and 40% of the general population sample had lifetime use 
of illicit substances. Statistical analysis indicates that this implies a threefold risk in patients 
compared to the general population. This suggests that the risk is greater in BD than in the general 
population not only to develop excessive substance use, but also to use illicit drugs. The 
(hypo)manic symptom of “excessive involvement in pleasurable activities” may involve 
experimenting with drugs. However, several studies have found increased impulsivity and novelty 
seeking even in euthymic BD patients (Nery et al., 2008; Swann et al., 2001), and these traits have 
also been linked to substance use (Brady et al., 1998; Fergusson et al., 2008). Another model 
proposed to account for the propensity to substance use in BD is a hypersensitive “Behavioral 
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Approach System” (BAS). The BAS is conceptualized as a psychobiological system regulating 
approach to reward or appetitive stimuli (Depue & Iacono, 1989). BAS sensitivity has been linked to 
an increased risk of (hypo)manic episodes (Alloy et al., 2008), and a prospective study showed that 
high BAS sensitivity predicted SUDs in a sample of BD patients (Alloy et al., 2009). The authors 
hypothesize that these characteristics represent shared vulnerability factors for BD and SUDs. The 
findings on impulsivity, novelty seeking and BAS sensitivity in BD may explain our results showing 
an increased propensity towards substance use even among patients that have not developed 
excessive substance use.  
5.3.2 The relationship between excessive substance use and the outcome of bipolar 
disorder 
Our results did not give many indications that the presence of excessive substance use was 
associated with more a more severe course of the BD. There were however several indicators of a 
poorer functioning in the excessive substance use group compared to the no use group, including 
shorter education length and lower employment rates. Although earlier studies are inconsistent, 
our findings of poorer functioning in the excessive substance use group are in line with several 
studies showing increased occupational impairment (Haro et al., 2006; Tohen et al., 1990), reduced 
educational level (Sonne et al., 1994; Weiss et al., 2005) and worse global functioning (Cardoso et 
al., 2008; O'Connell et al., 1991) associated with comorbid SUD. The excessive substance use group 
also had poorer compliance to medication, which is in accordance with earlier and more consistent 
findings (Manwani et al., 2007; Sajatovic et al., 2009). Whether relationships between substance 
use and impairment are due to negative effects from the excessive substance use, or the 
impairment was present before the excessive substance use developed (and thus may instead 
comprise risk factors for substance abuse), cannot be determined on the basis of the present 
findings.  
Indicators of disease severity in BD, such as current depressive or manic symptoms, 
number of affective episodes or BD type, did not differ between patients with or without excessive 
substance use. A possible explanation of the lack of associations between excessive substance use 
and current affective symptomatology is the fact that we investigated lifetime and not current 
excessive substance use; an unknown proportion of the patients may have recovered from their 
SUD or seized using substances excessively when symptom assessment was conducted. However, 
we found that the consumption of both alcohol and drugs the last 6 months were higher in patients 
with excessive substance use compared to patients without, demonstrating that there were 
significant differences in recent substance use. Furthermore, the finding of no differences in 
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current affective symptomatology is in line with several other studies finding no differences across 
groups defined by SUD in these variables (Goldberg et al., 1999; Sonne et al., 1994).  
We found no significant differences in measures of remission between patients with or 
without excessive substance use. This was unexpected, since prolonged affective episodes are 
found quite consistently by earlier research (Weiss et al., 2005). However, there were numerical 
differences between the groups in the expected direction on these variables, so this difference 
could reach statistical significance in a larger sample (i.e. findings may represent a type II error). 
Furthermore, the present finding of no relationship between excessive substance use and number 
of affective episodes is in line with previous research (Nolen et al., 2004) although this is sparsely 
investigated. Finally, the similar distribution of bipolar subtypes across the groups in our study 
converges with some studies (Weiss et al., 2005), but is contrary to those finding higher SUD rates 
in bipolar I disorder compared to bipolar II disorder (Chengappa et al., 2000; Regier et al., 1990).  
Our findings of no differences in BD illness severity between patients with or without 
excessive substance use is in accordance with a study on BD I disorder with or without SUD  for 
several proxies for BD severity (Goldstein & Levitt, 2008). It also converges with the findings of a 
recent study where no differences in clinical characteristics were found between patients with a 
low, medium or excessive use of alcohol (van Zaane et al., 2010). The hypothesized potential for 
substance abuse to trigger BD in individuals with low constitutional vulnerability for the disorder 
(Strakowski et al., 2000; Winokur et al., 1998) could partly account for these negative findings: A 
lack of worsening of BD illness characteristics in the presence of SUD may be explained by a lower 
vulnerability for BD. Furthermore, according to the behavioral sensitization hypothesis, 
environmental factors such as substance use play a major role in the early course of the BD, while 
the further course is relatively independent from the influence of external factors (Post, 1992).   
The trend towards increased suicidality rates, as well as the lower GAF S scores found in 
the excessive substance use group in the present study, could be signs of a poorer general 
psychiatric outcome that is not mediated by a more severe course of the BD. Increased suicidality is 
seen in a number of psychiatric disorders and has been found associated with SUD alone 
(Innamorati et al., 2008), and with the combination of SUD and a variety of psychiatric disorders 
(Bulik et al., 2008; Gentil et al., 2009; Limosin et al., 2007). Thus the increased suicidality may be 
more strongly related to the excessive substance use per se than to a more severe BD course. In 
summary, excessive substance use does not appear to be related to more severe specific BD illness 
characteristics, but to a more severe general psychiatric outcome in terms of worsening of 
unspecific and global clinical features frequently seen in association with SUDs alone (such as 
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poorer GAF symptom scores and increased suicidality). This may also be related to the burden of 
having two disorders. 
5.3.3 The relationship between excessive alcohol and cannabis use and the age at onset 
of bipolar disorder 
Excessive use of cannabis was associated with an earlier onset also after adjusting for potential 
confounders. Excessive alcohol users had a later onset, were older at assessment and had a later 
onset of the excessive use, a lower prevalence of family history as well as lower rates of use of 
other substances compared to the cannabis users. Our findings also suggest differences in 
sequencing: for the alcohol users, the mean AAO was earlier than the mean age at onset of the 
excessive substance use, while for the cannabis users the mean AAO was later than the mean age 
at onset of the excessive substance use. There was, however, no interaction effect between type of 
substance use and sequencing on AAO.  
One possible explanation for the association between early onset and excessive cannabis 
use could be that it is a cohort effect, i.e. that people born in the last decades may be at greater 
risk for developing excessive cannabis use than patients born earlier due to changes in use trends 
or availability. However, since excessive cannabis use was associated with AAO also after adjusting 
for current age, cohort effects cannot explain the finding. Furthermore, excessive cannabis use was 
associated with an earlier onset after adjusting for possible confounders such as family history and 
excessive use of other substances. Excessive alcohol use was however not independently 
associated with AAO. The later onset in alcohol users compared to cannabis users, and the 
independent predictive effect of cannabis as opposed to alcohol on AAO, may indicate that 
different mechanisms are involved in the relationships between the development of BD and these 
two most frequently used substances. Although somewhat speculative, our findings may indicate 
that cannabis has potential to trigger BD, while alcohol to a greater degree is used to self-medicate 
mood symptoms. 
The association between cannabis use and early onset in the current study was present 
even after adjusting for sequencing and thus appears to exist both when the excessive use 
develops before, and after the BD. This is in contrast to earlier findings of a later onset in BD 
secondary to cannabis compared to primary BD (with or without cannabis use disorder)(Strakowski 
et al., 2007). This discrepancy could be due to differences in methodology and sample 
characteristics. One explanation may be the high family history rates in our sample of excessive 
cannabis users, an area where no data were presented in the previous study. Higher family history 
rates may indicate high vulnerability for BD, which may interact with excessive cannabis use to 
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cause an early onset in these patients. The complex relationship between AAO, type of substance 
used, sequencing and family history should be further explored in a larger sample allowing 
comparisons of several subgroups. 
Our findings also indicate that an early onset increases the risk of subsequently developing 
excessive cannabis use. This is in accordance with earlier findings of an association between early 
onsets and drug abuse (Perlis et al., 2004; Wilens et al., 1999), which may have several 
explanations. Some authors have proposed that patients with early onsets may share a common 
increased genetic vulnerability mediating both BD and excessive drug use (Lin et al., 2006). Family 
history did not independently predict AAO in the present study. However, the family history rates 
of affective/psychotic disorders among the cannabis users were high. Having a close family 
member with a severe psychiatric disorder in addition to experiencing affective episodes early in 
life may also represent a substantial psychosocial burden, leaving the patient at increased risk for 
illicit substance use.  
When patients with or without excessive substance use were compared in paper I, we 
found no difference in AAO. However, differences appeared when patients were divided into 
primary and secondary BD, and grouped according to type of substance used. Thus, the association 
between excessive substance use and AAO appears to depend on which substances that are used, 
and whether the BD is primary or secondary to excessive substance use. 
It may seem contradictory that excessive substance use is associated with the onset of the 
BD (Paper II), whilst it appears not to be associated with the symptoms or course of the BD (Paper 
I). This apparent divergence may be explained by the kindling/behavioral sensitization hypotheses, 
postulating that environmental factors play a major role in the early course of the BD which 
eventually “lives it’s own life” relatively independently from external events such as substance use 
(Post et al., 1986). Furthermore, relationships with clinical characteristics and excessive substance 
use may have been found in the present study if we had investigated cannabis use separately, as 
indicated by other studies (Strakowski et al., 2007; van Rossum et al., 2009).  
5.3.4 Excessive substance use and the onset of bipolar disorder 
Even though the potential to trigger BD in vulnerable individuals has been proposed for both 
alcohol and cannabis (Strakowski et al., 2007; Winokur et al., 1995), the potential of cannabis may 
be greater. This is in line with two recent studies of acutely ill patients with a broad spectrum of 
psychotic disorders, showing that cannabis abuse/dependence was associated with an earlier onset 
of the psychotic disorders after adjusting for abuse/dependence of other substances including 
alcohol (Gonzalez-Pinto et al., 2008; Öngür et al., 2009). Our findings indicate that the association 
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between an earlier onset and excessive cannabis use is present also in a pure BD sample. 
Furthermore, it is fairly well established that cannabis use is a risk factor for the development of 
psychosis/schizophrenia in the presence of other risk factors such as genetic vulnerability (D'Souza 
et al., 2009). The fact that schizophrenia and BD have many clinical features in common as well as 
overlapping pathophysiology (Murray et al., 2004) increases the plausibility that cannabis use may 
act as a risk factor even in BD. There is also growing evidence from prospective epidemiological 
studies that cannabis use increases the risk for developing manic symptoms and BD (Henquet et al., 
2006; van Laar et al., 2007), while alcohol abuse seems to increase the risk for depressive rather 
than manic symptomatology (Baethge et al., 2008; Fergusson et al., 2009). Furthermore, in a recent 
study on prodromes of first manic psychotic episode, 68% of patients were found to have 
substance use disorders in the prodromal phase out of which 82% used cannabis (Conus et al., 
2010).  
The present finding that secondary BD (relative to primary BD) was associated with a later 
onset is highly consistent with earlier studies (DelBello et al., 1999; Falk et al., 2008; Feinman & 
Dunner, 1996; Fossey et al., 2006; Strakowski et al., 1996; Strakowski et al., 2005; Strakowski et al., 
2007). We also demonstrate that this effect remains significant even after adjusting for several 
variables known to be associated with AAO (gender, BD type, family history, type of substance 
used); further supporting the hypothesis that excessive substance use may trigger BD. We do not, 
however, replicate earlier findings that family history rates are lower in secondary BD compared to 
primary BD (DelBello et al., 1999). We do, however, demonstrate that the family history rates are 
higher among the cannabis users compared to the alcohol users and the non-users. Patients’ 
reports of family history of psychiatric disorders is a somewhat crude measure (Roy et al., 1996), 
which may explain these inconsistencies. Furthermore, the full range of vulnerability markers and 
risk factors for BD are not yet known, thus other factors may have confounded this result.  
5.3.5 The relationship between excessive substance use and treatment delay 
We found that when excessive substance use preceded BD onset, the risk of a long treatment delay 
was reduced. This finding indicates that excessive substance does not appear to represent a barrier 
for receiving adequate pharmacological treatment in BD. This is in line with previous studies 
showing that patients with other co-occuring mental illness and SUDs are more likely to utilize 
health care services than patients with only one disorder (Jacobi et al., 2004; Regier et al., 1993; 
Urbanoski et al., 2007; Wu et al., 1999). Our finding also aligns with “Berkson’s bias” showing that 
different disorders in the same individual independently influence help-seeking and need for care 
(Berkson, 1946), and thus accelerate treatment initiation in individuals with both BD and excessive 
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substance use. Furthermore, this finding converges with a recent study showing higher rates of 
SUDs in patients with recognized BD compared to patients with unrecognized BD (Mantere et al., 
2008).  
Focusing only on patients without excessive substance use at onset of the BD, we found 
that longer treatment delays were associated with an increased risk for developing excessive 
substance use. This risk was still present after adjusting for the influence of other predictors of 
substance use.  Our finding here is thus in line with the self medication hypothesis (Khantzian, 
1997) or the general “alleviation of dysphoria” model (Mueser et al., 1998), suggesting that 
psychiatric patients use substances as an attempt to deal with increasing symptoms or 
psychological distress. These theories have gained support from several other studies (Bizzarri et 
al., 2007; Bolton et al., 2009; Healey et al., 2009; Weiss et al., 2004). An alternative explanation of 
the association between treatment delay and subsequent excessive substance use is that 
substance using patients are more reluctant and less compliant with medication (Baldessarini et al., 
2008; Goldberg et al., 1999; Keck, Jr. et al., 1998; Manwani et al., 2007). This appears less likely in 
the present study as there was no difference in the proportion that used medication in excessive 
substance users and non-users.  
5.3.6 Strengths and limitations of the study 
This is a study with a naturalistic design of BD patients in a catchment area-based specialized 
psychiatric treatment. Reliability-testing was performed for the most central assessments, and the 
patient sample was well characterized. The substance use assessments were particularly 
comprehensive.  
The present study’s excessive substance use category is more broadly defined than DSM-IV 
SUDs, which have been the main focus in earlier studies. There is little knowledge about the 
appropriate cut-off for harmful substance use in patients with severe mental illness. Investigating a 
broader range of substance use than strict DSM-IV abuse or dependence in clinical studies on BD, 
such as the present study’s excessive substance use, may help to clarify this. Furthermore, 
considering excessive substance use based on frequency patterns and not only on harmful 
behavioral or psychological consequences (on which SUD criteria are based) adds to the current 
knowledge on substance use in BD. These advantages were considered to outweigh the 
disadvantages of using a substance abuse definition that diverges somewhat from previous studies. 
Also, there are several indications from the present study’s findings that excessive substance use is 
a valid category when investigating BD, such as its associations with functional characteristics, AAO 
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and treatment delay. Furthermore, the study demonstrates that patients with a frequent and 
sustained use of substances do not necessarily fulfill SUD diagnostic criteria. 
The study has some limitations. The cross-sectional design does not provide direct 
information on causal relationships. Some of the same limitations apply to longitudinal naturalistic 
studies. However, the possibility to study the effects of psychoactive substances experimentally in 
humans is highly limited, due to the ethical issues related to exposure to potentially (and well 
known) harmful conditions. Cross-sectional naturalistic studies may give indirect indications of 
causal relationships, and challenge or support prevailing causal theories and -hypotheses.  
Information on temporal relationships, i.e. what comes first and last, will give some 
information regarding what may possibly be either the cause or the effect. This is the idea behind 
using the primary and secondary BD categories (in paper II and III). There is however a risk for 
misclassification in these categories. The possibility of recall bias is of special relevance in this 
context, and has already been discussed. Furthermore, the onset of affective symptoms and 
excessive substance use may be intertwined. E.g. there may be cases in which the excessive 
substance use seems to be primary, however is used in a period of prodromal affective symptoms 
(and thus could have been classified as secondary). Using a diagnostic instrument specifically 
designed to determine the sequencing of psychiatric symptoms and substance use disorders such 
as the PRISM (Caton et al., 2000) could have facilitated more reliable classifications in some cases. 
This interview was however not available in a Norwegian translation at the time of the assessments 
for the current study. Furthermore, in cases where the development of the different symptoms is 
highly intertwined, even strictly operationalized criteria may not determine what is “truly” primary 
or secondary. In only 6 cases in the current study the excessive substance use and the first affective 
episode developed within the same year. Thus, these highly indeterminable cases thus do not 
constitute a great proportion of the total sample.  
The sample in the current study was too small to investigate and compare some subgroups 
of interest. The relatively small sizes of the subgroups in both papers I and II imply a risk for type II 
errors. However, in paper I there are few substantial numerical differences between the groups, 
thus even a substantial increase in sample size would not lead to additional significant differences. 
In paper II, there are substantial differences between the groups in spite of the relatively small 
group sizes.   
The current study did not include information on patient’s subjective experience with 
excessive substance use, e.g. rationale for using and perceived effect of different substances. Such 
information would have been valuable especially for clarifying questions regarding possible self-
medication effects raised in paper III.  
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The findings regarding risk factors for treatment delay in paper III may be biased by the 
decision to dichotomize the treatment delay variable (≤ or > 2 years). However, the alternatives of 
using parametric statistics on a highly skewed variable or using non-parametric statistics (without 
the possibility for multivariate analyses) would most likely have generated less valid findings. 
Furthermore, all the identified predictors (except from the presence/absence of psychosis) were 
highly significant, thus appear to be relatively robust findings. 
The end-point of treatment delay in paper III was defined as the initiation of adequate 
pharmacological treatment (defined as mood-stabilizing or anti-psychotic agents). This definition 
should not be interpreted as normative for a complete and satisfactory treatment for patients with 
BD, as there is growing evidence that psychotherapeutic interventions are crucial ingredients in the 
treatment of BD (Fountoulakis et al., 2009; Miklowitz & Scott, 2009). However, based on current 
knowledge of effective treatment of BD, it is considered to be the best single indicator of adequate 
treatment. 
5.4 Theoretical implications 
To what extent do the findings from the current study support or contradict the prevailing 
hypotheses on the comorbidity of severe mental disorders and SUDs?  
Common factor models: Our findings do not appear to be at odds with common factor 
models, which postulate that common risk factors may increase the risk for both disorders. The 
earlier onset of BD among patients with excessive cannabis use may support the notion that 
common factors (such as genes, psychosocial stressors or personality traits) have increased the risk 
for both disorders. Furthermore, the high rate of lifetime use of illicit substances in patients 
compared to the general population may support a common factor model, in that the propensity 
to illicit substance use seems to be present even in BD individuals that have not developed 
excessive substance use. 
Secondary substance use disorder models: Our findings do not seem to be in conflict with 
secondary SUD models, which propose that severe mental illness may cause SUDs. Rather, the 
finding that treatment delay was associated with subsequent excessive substance use supports the 
notion that excessive substance use may be an attempt to self-medicate symptoms or distress, i.e. 
that BD may cause excessive substance use. 
Secondary psychiatric disorder models: Secondary psychiatric disorder models, in which 
substance abuse is suggested to cause or precipitate severe mental illness, are not contradicted by 
the present study’s findings. The later onset in secondary BD and the earlier onset in individuals 
with preceding excessive cannabis use found in the current study, both support the notion that 
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excessive substance use may trigger BD even though this may seem incongruous. The higher AAO 
in secondary BD may be explained by a low constitutional vulnerability, and that a prolonged 
excessive substance use was necessary to elicit the BD in these individuals. The earlier onset in 
patients with excessive cannabis use prior to BD onset may be explained by either a high 
constitutional vulnerability interacting with cannabis use, or that cannabis is a substance with high 
potency for precipitating BD. The fact that our sample of excessive cannabis users had high rates of 
family history of affective/psychotic disorders supports the former hypothesis. 
Bidirectional models: The findings of the present study contain little data to challenge or 
support the theory that excessive substance use increases the risk for BD and vice versa within 
individuals.   
In conclusion, the findings of the present study appear to support the notion that the 
strong association between BD and excessive substance use may stem from many different 
mechanisms and relationships, i.e. that no single mechanism can explain all co-morbid cases. Such 
mechanisms may be that substance abuse precipitates BD, that patients self-medicate symptoms 
of BD with alcohol and drugs, and that common factors such as genes, elevated impulsivity or 
behavioral approach system sensitivity increase the risk for both disorders. More than one of the 
mechanisms may also operate within the same individual. 
5.5 Clinical implications 
The findings of the current study may have important implications for the treatment of BD 
patients. Because of the increased functional impairment and treatment non-compliance 
associated with excessive substance use, substance use should be targeted in treatment before the 
clinical signs of abuse or dependence have developed. In fact, due to the high rate of lifetime use of 
illicit substances among the patients and the possibility that all BD patients have an increased 
propensity for substance abuse, addressing substance use at an early point of the treatment is of 
great importance. Furthermore, individuals at high risk for developing BD should be warned about 
the possible precipitating effect of cannabis use.  
The finding that the risk for onset of excessive substance use increases with increasing 
treatment delay implicates that early identification and treatment of BD is crucial. Thus, although 
the focus and knowledge on BD appears to be increasing, further education and information on BD 
for e.g. general practitioners and other primary health care providers may be needed. As much as 
28% of the patients in the current sample had never received adequate pharmacological 
treatment. These were mainly patients with BD II or no history of psychosis. There are clear 
indications that even these patients benefit from such treatment (Grunze et al., 2004). Thus, effort 
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should be made to make pharmacological treatment more accessible even for BD patients without 
the most severe clinical presentations.  
It should also be of considerable value for both the clinic and authorities involved in planning 
and reforming psychiatric treatment to know that excessive substance use does not appear to be 
an obstacle for initiation of pharmacological treatment of BD.   
5.6 Implications for future research 
This is a clinical study, and the following recommendations for future research will focus on clinical 
areas. However, the relationship between BD and excessive substance use also needs to be further 
investigated through research on biological mechanisms.  
In the current study, different AAOs, as well as different directions for the association 
between treatment delay and excessive substance use, depending on the temporal relationship 
between the onsets of BD and excessive substance use were discovered. Thus, differentiating 
between primary and secondary BD appears to be necessary to discover important associations 
between substance use and several features of BD. There may also be differences in clinical 
characteristics between these groups. However, such an investigation was not part of the aims of 
the current study, but should be addressed in future research. 
The complex relationship between AAO, type of substance used, sequencing and family 
history should be further explored in a greater sample allowing comparisons on several subgroup 
levels. Ideally, the sample should allow subdivision according to different degrees of familial 
loading in addition to the other subgroups suggested. Furthermore, in order to better clarify causal 
relationships regarding the impact of excessive substance use on the course and symptoms of BD 
and whether excessive substance use may precipitate BD, longitudinal and epidemiological studies 
are needed. Future research should also aim to clarify whether excessive substance use may trigger 
subsyndromal symptoms, affective episodes or the disease entity of BD. 
Furthermore, increased knowledge of subjective experiences of substance use such as 
motives and perceived effects is needed to further evaluate secondary substance use models (such 
as self-medication hypotheses) and improve intervention strategies. The recently developed 
experience sampling methodology may be a worthwhile approach to such research, as it enables 
momentary and longitudinal assessment of individual experiences such as emotions, stress, 
substance craving and -use during daily life (Myin-Germeys et al., 2009).  
Given the high risk for excessive substance use in BD, searching for potential resilience factors 
in BD subjects not developing excessive substance use could also be a worthwhile approach for 
future studies. Such knowledge would facilitate planning of preventive strategies. 
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6 CONCLUSIONS 
The most important findings of the present study are that excessive substance use is associated 
with poorer functioning but not with more severe clinical characteristics, and that excessive 
cannabis use is associated with an earlier age at onset of bipolar disorder. Furthermore, patients 
with excessive substance use prior to the onset of bipolar disorder have a higher likelihood for 
short treatment delays compared to patients without, whereas long treatment delays are 
associated with an increased risk for subsequent excessive substance use. 
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Appendix 
 
Table 1. DSM-IV affective episode criteria. 
Major depressive episode: 
- a period of at least 2 weeks with either depressed 
mood or loss of interest or pleasure in almost all 
activities 
- at least 3 (4 if only depressed mood or loss of interest) 
of  the following symptoms must be present:  
 changes in appetite or weight  
 sleep or psychomotor activity 
 decreased energy 
 feelings of worthlessness or guilt 
 difficulty thinking, concentrating or making 
decisions 
 recurrent thoughts of death or suicidal ideation, 
plans or attempts 
 
- may involve psychotic symptoms in terms of 
delusions, hallucinations or thought disorders 
 
Manic episode: 
- a distinct period of at least 1 week (or less if 
hospitalization is required) with either abnormally and 
persistently elevated, expansive or irritable mood  
- at least 3 (4 if irritable mood only) of the following 
symptoms must be present:  
 inflated self-esteem or grandiosity 
 decreased need for sleep 
 pressure of speech 
 flight of ideas 
 distractibility 
 increased involvement in goal-directed activities 
or psychomotor agitation 
 excessive involvement in pleasurable activities 
with a high potential for painful consequences 
 
- the disturbance is not sufficiently severe to cause 
marked impairment in social or occupational 
functioning or to require hospitalization 
- may involve psychotic symptoms in terms of 
delusions, hallucinations or thought disorders 
 
Hypomanic episode: 
- a distinct period of at least 4 days with either 
abnormally and persistently elevated, expansive or 
irritable mood  
 
- the list of symptoms is identical to that of mania 
 
- the disturbance is not sufficiently severe to cause 
marked impairment in social or occupational 
functioning or to require hospitalization 
 
- may not involve psychotic symptoms  
 
Mixed episode:  
 
- a period of at least 1 week in which the criteria are 
met both for a major depressive episode and a manic 
episode 
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Table 2. Lifetime substance use registration form.1 
 
Lifetime substance use: (fill inn) (0=never/occasionally, 1=monthly, 2=weekly, 3=daily) 
 
 
1 Incl. methamphetamine, khat and  Ritalin, 2 Incl. crack and coke leaves, 3 Incl. marihuana and hashish, 4 Incl. morphine, 
Methadone, Dolcontin, Ketogan, Petidin, Temgesic, Paralgin Forte etc.  5 Incl. LSD, mescaline, mushrooms, PCP etc. 6 
Incl. lighter fluid, gasoline, glue etc. (for sniffing)  7 Incl. sedative (Vival, Rohypnol, Rivotril etc.) and pain-killing 
(Somadril) medication used without prescription or exceeding the prescription. 
 
Instructions for completing the substance use section:  
Lifetime: Tick if substance was ever used (at least one clear episode).  
Onset: Age at first time substance was used.   
Duration: Total number of years the substance was used. (Used once during one year=1 year)  
Age interval: Within each age interval, a code is used to indicate how frequently the substance is 
used: 
  
0 – no use or occasional use  
1 – Monthly use  
2 – Weekly use 
3 – Daily use  
  
i.v. : Tick if substance was used intravenously.  
 
Alcohol:   
Alcohol intoxication implies that the person drinks to get intoxicated or drunk. 
  
Please note: Indicate whether the substance use has varied within each interval, especially if there 
have been periods with high consumption of alcohol (binge drinking) or a more regular 
consumption. Using the interviewees own word is suggested. 
  
Notes: 
                                                          
1 This instrument was translated to English for the purpose of presentation in this thesis and is not an official 
translation. 
  Lifetime Onset Duration 12-15 16-20 21-27 28-44 45-60 60+ i.v. 
Alcohol - use   
Alcohol - intoxication  
Amphetamines1   
Cocaine2   
Cannabis3   
Ecstasy   
Heroine   
Other opiates4   
Hallucinogenes5   
Solvents6   
Pharmacological agents7   
I
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Background: There is a strong association between bipolar disorder (BD) and substance use disorder (SUD). The
clinical and functional correlates of SUD in BD are still unclear and little is known about the role of excessive
substance use that does not meet SUD criteria. Thus, the aims of the current study were to investigate lifetime
rates of illicit substance use in BD relative to the normal population and if there are differences in clinical and
functional features between BD patients with and without excessive substance use.
Methods: 125 consecutively recruited BD in- and outpatients from the Oslo University Hospitals and 327 persons
randomly drawn from the population in Oslo, Norway participated. Clinical and functional variables were assessed.
Excessive substance use was defined as DSM-IV SUD and/or excessive use according to predefined criteria.
Results: The rate of lifetime illicit substance use was significantly higher among patients compared to the
reference population (OR = 3.03, CI = 1.9-4.8, p < .001). Patients with excessive substance use (45% of total) had
poorer educational level, occupational status, GAF-scores and medication compliance, with a trend towards higher
suicidality rates, compared to patients without. There were no significant group differences in current symptom
levels or disease course between groups.
Conclusion: The percentage of patients with BD that had tried illicit substances was significantly higher than in
the normal population. BD patients with excessive substance use clearly had impaired functioning, but not a worse
course of illness compared to patients without excessive substance use. An assessment of substance use beyond
SUD criteria in BD is clinically relevant.
Background
Comorbid bipolar disorder (BD) and substance use dis-
order (SUD) have been found to be highly prevalent in
both epidemiological and clinical studies, with rates of
SUD in subjects with BD ranging from 35-60% [1-6].
The high prevalence is found across different age groups
and also in first episode BD samples [7,8].
So far, most studies in BD have investigated only sub-
stance use fulfilling SUD criteria. Investigating a broader
range of substance use in BD could be relevant because
people with severe mental disorders are more likely to
experience negative consequences from using relatively
small amounts of psychoactive substances [9]. Moderate
alcohol consumption in BD is associated with more
severe manic symptoms compared to abstinence, and to
poorer social and familial adjustment and increased
health-care use [10]. To the best of our knowledge, only
one study assessed substance use in BD more globally,
reporting that 46% had SUDs and 8% had SUD-sub-
threshold substance use. In addition, the authors indi-
cated that another substantial proportion used illicit
substances occasionally [11].
Clarifying whether there is an increased use of sub-
stances in BD may increase our understanding of the
psychopathology underlying the increased risk of abuse
or dependence. Although most studies show a large pre-
valence of BD and SUD comorbidity, the rates vary
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widely. This variation could be mirroring differences in
substance use in the general population where the BD
sample is recruited. In a smaller sample from an earlier
part of our ongoing study, we showed elevated rates of
lifetime use of illicit substances among patients with
psychotic disorders (including BD) compared to the
general population [12], and differences in patterns of
substance use between schizophrenia and BD [13]. Due
to the small number of patients with BD included in
our earlier report, a separate comparison of BD patients
with the general population sample was not implemen-
table. Thus, there is a need for studies comparing BD
subjects with reference populations on substance use
and they should be done with samples from the same
geographical area within the same time period.
In the current literature, BD with comorbid SUD is
consistently referred to as associated with a poorer dis-
ease course and with reduced functioning compared to
BD without SUD. The findings regarding the effects of
SUD on BD are however divergent. To explore this
more thoroughly we did a search in PubMed (terms
bipolar disorder, substance abuse and outcome), and in
addition tracked all cited references in key publications
(Additional file 1). The main finding from this search
was that the only consistently reported findings were
delayed recovery and lower remission rates [14-22] as
well as faster relapses [14,23-25] in groups of BD
patients with SUD (both lifetime/current substance -
and/or alcohol use disorders) compared to BD without
SUD. Furthermore, there appears to be extensive evi-
dence for elevated suicidality rates in BD with SUD
compared to BD without [18,20,26-37], although several
studies also report no significant differences [19,38-42].
Medication compliance rates are also relatively consis-
tently reported to be lower in BD with SUD compared
to BD without [18,19,29,43-46] although a few studies
report lack of differences [38,42]. Another consistent
finding is that the prevalence of psychotic symptoms
does not appear to be elevated among BD patients with
SUD compared to patients without [18,19,28,38,47,48],
and there is neither a tendency towards increased num-
bers of affective episodes [19,27,31,48,49].
The findings are more divergent regarding rapid cycling;
as some studies did [38,40,50-52] and some did not
[19,29,53] find this to be more prevalent in the SUD
patients. The same inconsistency is found for the preva-
lence of mixed episodes, some studies found this phenom-
enon to be more common [14,18,39,50,54] while others
did not [17,47,55] in the SUD patients. There are
also inconsistencies regarding age of onset for BD;
here some report earlier onset for patients with
SUD [26,29-31,50,51,56,57] while others do not find any
differences compared to BD patients without SUD
[18,19,38,47,55,58]. Studies also diverge as to whether
affective symptoms are of increased severity in BD patients
with SUD compared to BD patients without
[18,21,26,39,42,47,49,50,59,60]. Furthermore, the number
of hospitalizations or days in hospital is found to be eleva-
ted in BD patients with SUD in some studies
[29,31,50,55,61-64] as opposed to in others
[18,26-28,38,48,56,65].
Findings concerning other functional variables such as
decreased global functioning [19,26,38,39,47,48,56,60,66],
social functioning [20,21,27,29,38,58,60,67], educational
level [19,20,26,31,38,50,56,60], and quality of life
[20,21,26,58,60,61] in BD with SUD also diverge. Finally,
some studies find lower employment status in BD with
SUD compared to BD without [21,24,29,67] while others
do not [28,43,50,56], and two studies even find better
employment rates in BD with SUD [19,61]. The current
evidence therefore suggests that BD with comorbid SUD
is clearly associated with worsening of some clinical and
functional characteristics: Length of affective episodes
and relapse rates, risks of suicidality and compliance to
medication. However, substance abuse does not appear
to be as consistently associated with a more severe
course and outcome as frequently indicated in the
literature.
In the present study, we aim at investigating differ-
ences in relevant outcome variables in a sample of BD
patients with and without substance use. The present
paper is based on a cross-sectional study of consecu-
tively referred patients with BD from a catchment-area
based psychiatric service, and a population survey of the
use of illicit substances in the same area within the
same time period. Our aims were to answer the follow-
ing questions:
1) Is the rate of lifetime use of illicit substances higher
in the patient sample than in the reference population?
2) Do patients with and without excessive substance
use, defined as SUD and/or excessive use, differ on clini-
cal and functional characteristics, in terms of disease
course variables, current symptom levels and
functioning?
Methods
Participants
125 patients with DSM-IV bipolar disorder (BD I n = 71
and BD II n = 54), participated in the study. The sample
is part of an ongoing study of schizophrenia and bipolar
disorder (the Thematically Organized Psychosis
Research - TOP study). The BD patients were consecu-
tively recruited between 2003 and 2007 from the psy-
chiatric units (in- and outpatient) of the three major
hospitals in Oslo. The exclusion criteria for all partici-
pants were: history of moderate/severe head injury, neu-
rological disorder, mental retardation, age outside the
range of 18-65 years, and not speaking a Scandinavian
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language. All participants gave informed consent, and
the project was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate.
A sample from the general population was used as a
reference group for rates of lifetime use of illicit sub-
stances, collected by the Norwegian Institute for Alcohol
and Drug Research (SIRUS). SIRUS regularly conducts
surveys of the Norwegian population’s consumption of
illicit substances by personal interviews via standardized
questionnaires. Subjects are randomly selected according
to a detailed selection protocol and weighted to age, gen-
der and address [68]. For the purpose of this study, we
used a reference group of 327 subjects from 2004 SIRUS
data for Oslo, with participants aged 18-65. There was no
age difference between the patient group and the refer-
ence group (35.6, SD 11.7 vs. 36.0, SD 12.0), but the pro-
portion of women was significantly greater in the patient
sample (64.8% vs. 51.4%, Χ2 = 6.59, df = 1, p = 0.010).
Clinical assessment
Clinical assessment was carried out by trained clinical
psychologists and psychiatrists. Diagnoses were estab-
lished using the Structured Clinical Interview for DSM-
IV, modules A-E [69]. General non-psychotic symptoms
were assessed by the Positive and Negative Syndrome
Scale (PANSS) [70], depressive symptoms with the IDS-
C [71], (hypo)manic symptoms with the Young Mania
Rating Scale (YMRS) [72] and current functioning by
the Global Assessment of Functioning Scale (GAF) [73],
split version [74]. The Medication Adherence Rating
Scale (MARS) [75] was used to measure compliance to
medication. A total of 103 patients (82.4%) completed
the MARS. Eight patients (6.4%) did not complete
because they were not using any medication at the time
of the evaluation. Among the patients not completing
the MARS, there was no significant difference in the
proportion with or without excessive substance use.
All interviewers were trained based on the training
program at UCLA (CA, USA) and participated in regu-
lar diagnostic consensus meetings. A good inter-rater
reliability was achieved with an overall kappa score of
0.77 (95% CI: 0.60-0.94). The reliability for symptom
assessments was also good, with an intraclass correlation
coefficient (1.1) of 0.71 for the PANSS general subscale,
and of 0.86 for both symptom and function GAF scores
(for details, see Ringen et al. 2007b).
Some of the variables frequently reported in the litera-
ture, like prevalence of mixed episodes and rapid
cycling, were not investigated in the present study, due
to a study design that did not focus on specific charac-
teristics of the affective episodes. Disease course was
assessed by means of SCID criteria, which lack the spe-
cificity needed for satisfactory reliability of such
phenomena.
Substance use assessments and excessive substance use
definitions
Patients were asked for age at first experience with drink-
ing alcohol and using non-alcoholic drugs (including non-
prescribed anxiolytic and hypnotic medicines). Lifetime
use of all substances through age intervals (age 12-15,
16-20, 21-27, 28-44, 45-60, 60+) was registered separately
in categories of daily, weekly, monthly or occasional/no
use within each interval, based on the possibility of differ-
ent use patterns and of differences in the pathophysiologi-
cal influence of substances across different age periods.
Predominantly daily use of alcohol and predominantly
weekly use of a non-alcoholic substance throughout an age
interval across a minimum of 4 years were considered
excessive, and substance use according to these definitions
is subsequently termed excessive use. Structured interviews
about substance use during the past 6 months were per-
formed. Alcohol use was assessed by number of units and
non-alcoholic substance use by number of incidents. Dif-
ferent non-alcoholic substances were asked for specifically
and the use was quantified by totaling the number of inci-
dents recalled. Urine samples were also collected and cor-
responded well with patients’ own reports of consumption
of non-alcoholic substances in previous weeks [13]. There
were no statistically significant differences among the
levels of substance use (number of units of alcohol or
number of incidences of use of non-alcoholic substances)
the last 6 months between patients fulfilling SUD criteria
and patients with excessive use. But these two groups
combined differed significantly from the patients with
neither SUD nor excessive substance use. Thus, for the
subsequent analyses, patients with SUD and patients with
excessive use were aggregated in an “excessive substance
use group“. Patients with none of these are subsequently
named “no use group“.
The mean age was 34.8 (SD 11.8) in the excessive sub-
stance use group and 36.2 (SD 11.2) in the no use group
(n.s.). In the excessive substance use group, 54% were
female, which was significantly different from the no use
group, where 74% were female (Χ2 = 5.608, p = 0.018).
93% were Caucasian in the excessive substance use
group, and 90% in the no use group (n.s.). Median dura-
tion of illness was 9.5 years (IQR 12) in the excessive
substance use group and 11.5 years (IQR 16.75) in the
no use group (n.s.).
Statistical procedure
All analyses were done using the Statistical Package for
the Social Sciences (SPSS) version 16.0. The limit for
significance was set to 0.05 (two-sided). Chi-square tests
and Fisher’s exact tests were used when investigating
group differences on categorical data. Group differences
in independent samples were explored with Student’s
t-tests and ANOVAs on normally distributed continu-
ous variables and Mann Whitney U-tests and Kruskal
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Wallis tests for variables with a skewed distribution. The
distribution of skewed variables is presented through
medians and interquartile ranges (IQR). Binary logistic
regression analysis was used for calculating odds ratios,
controlling for relevant variables. Correlations between
group membership, outcome measures and background
variables that might mediate their relationships were
explored through Pearson and Spearman rank correla-
tions. The presence of possible confounder variables was
explored through hierarchical multiple regression analy-
sis. The Kaplan-Meier Survival Analysis was used to
compare time in remission across the two groups.
For the analyses related to research question 2, the
levels of relevant demographic and clinical measures
were compared for the excessive substance use group
versus the no use group. Since the distribution of sex
was significantly different in the excessive substance use
group and the no use group, it was considered a poten-
tial confounder in the associations between group mem-
bership and outcome variables and possible mediating
effects were investigated.
Results
The prevalence of lifetime use of illicit substances was
65% in the patient sample and 40% in the general popu-
lation sample. When corrected for age and sex, the risk
of lifetime use of illicit substances was significantly and
three times greater in the patient sample compared to
the reference population (OR = 3.03, CI = 1.9-4.8,
p < .001).
The prevalence of SUDs and excessive substance use
are presented in Table 1.
Regarding clinical and functional outcome variables
(Table 2), we found that the no use group had significantly
more years of education than the patients with excessive
substance use (15.1, SD 2.9 versus 13.5, SD 2.6, p = 0.001).
The proportion that was employed/full time students was
significantly smaller in the excessive substance use group
(21% versus 45%, p = 0.006). We also found that the exces-
sive substance use group had significantly lower mean
GAF S and F scores than the no use group (52.9, SD 10.7
versus 59.7, SD 11.1, p = 0.001 and 50.3, SD 11.3 versus
57.2, SD 12.1, p = 0.002, respectively). Correlation analyses
revealed that number of years of education correlated with
the excessive substance use group (Pearson’s r = -0.29,
p = 0.001), and GAF S and F scores (GAF S: Pearson’s
r = 0.22, p = 0.016, GAF F: Pearson’s r = 0.21, p = 0.018).
After correction for number of years of education, age and
sex, there was still a significant association between exces-
sive substance use and lower GAF S score (group mem-
bership entered as last variable, b = -0.24, p = 0.009), and
lower GAF F score (b = -0.20, p = 0.034). Furthermore,
the excessive substance use group had a significantly
higher median MARS score, i.e. was less compliant by
self-report than the no use group (8, IQR 5 versus 7, IQR
3, p = 0.010). There was also a strong trend that the exces-
sive substance use group had more suicide attempts than
the no use group (p = 0.053).
We found no significant differences in affective and
general symptomatology as measured by the IDS-score,
YMRS-score or PANSS general score between the
patients with and without excessive substance use (Table
2). The proportion of patients in remission was not sig-
nificantly different across the two groups, nor was time
in remission. No significant differences were found
between the groups in age at onset of BD, number of ele-
vated episodes (manic/hypomanic), number of depressive
episodes, or bipolar subtype distribution (BD I vs. BD II).
No significant differences between the groups were
found in lifetime prevalence of psychotic symptoms.
Regarding the latter, a separate analysis comparing
patients that only excessively used psychoactive sub-
stances known to induce psychotic symptoms (cannabis
and centrally stimulating agents) with the no use group
revealed no significant differences (Χ2 = 0.059,
p = 0.564). No significant differences were found regard-
ing lifetime hospital admission or total number of admis-
sions. Among the ones admitted, there was a trend that
the duration of admissions was shorter in the excessive
substance use group (p = 0.056). These analyses were
repeated for only patients fulfilling SUD criteria versus
the no use group (excessive use patients excluded),
revealing no additional significant differences between
the two groups. To investigate whether alcoholic and
non-alcoholic substances influenced outcome in different
directions, the alcoholic and non-alcoholic excessive sub-
stance use groups were compared with the no use group
separately. This yielded no new significant associations.
Discussion
The main findings of the present study are that patients
with BD had a significant increase (OR of 3) of lifetime
Table 1 Prevalence of lifetime substance use disorders
and of excessive use in patient sample, N (%)
N = 125
SUD total 38 (30.4)
Alcohol use disorder 26 (20.8)
Cannabis use disorder 15 (12.0)
Other non-alc. substance use disorder 14 (11.0)
Excessive use total 18 (14.4)
Excessive alcohol use 7 (5.6)
Excessive cannabis use 13 (10.4)
Excessive use other non-alc. substances 2 (1.6)
SUD + excessive use 56 (44.8)
SUD and excessive substance use are here mutually exclusive categories.
Within these categories, some patients meet the criteria for two or more
substance use disorders or can excessively use two or more substances.
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use of illicit substances compared to the general popula-
tion, and that excessive substance use was associated
with poorer functioning but not with worse illness
course characteristics or current symptom levels.
To the best of our knowledge, this is the first study to
report lifetime illicit substance use in a clinical sample
of BD patients compared to the reference population.
Our data indicate that the risk is greater than in the
general population not only to develop SUDs, but also
to use such drugs at a SUD-subthreshold level. Despite
large research efforts, the mechanisms involved in the
increased substance use in BD are not known. Several
studies have found increased impulsivity and novelty
seeking in BD patients [76,77], which have also been
linked to substance use [78,79]. This could partially
explain the increased tendency to experiment with and
excessively use substances among subjects with BD [80].
The same could be true for Behavioral Approach System
(BAS) dysregulation, in which high BAS sensitivity has
been linked to both increased risk of (hypo)manic epi-
sodes [81] and substance abuse [82]. Searching for
potential protecting factors in BD subjects not develop-
ing SUD could be a worthwhile approach for future
studies.
The total alcohol use disorder rate of 21% found in
the present study was in the lower range of earlier
clinical reports on samples consisting of both BD I and
II disorders [20,30,83], and the higher SUD rates in
males compared to females is in accordance with earlier
findings [57,58]. Thus, the somewhat higher proportion
of females in our sample could explain the lower alcohol
use disorder rate. Furthermore, both drug use and alco-
hol use patterns differ between countries and cultures.
The average alcohol intake in Norway is significantly
lower than the European continent, the UK and the US
[84,85], which could also explain the lower risk of alco-
hol use disorder in the patient group in the present
study.
There were several indicators of a poorer functioning
in the excessive substance use group compared to the
no use group, including length of education and
employment rate. The hierarchical multiple regression
analyses also indicated direct associations between
excessive substance use and lower GAF scores that were
not mediated by years of education. Although earlier
studies are inconsistent, our findings of poorer function-
ing in the excessive substance use group are in line with
several studies showing greater functional impairment
associated with comorbid SUD [20,21,29,60]. The exces-
sive substance use group also had poorer compliance,
which is in accordance with earlier research [45,46]. The
trend towards shorter hospital admissions found in the
Table 2 Clinical course and functional outcome variables in the “excessive substance use” group versus the “no use”
groups
Excessive substance No use Test statistics/p-value Effect sizes
use group, N = 56 group, N = 69
IDS-C, median (IQR) 16.5 (17) 13.5 (20) U = 1640.5, p = 0.853a
YMRS, median (IQR) 2 (3) 2 (5) U = 1730.5, p = 0.393a
PANSS general, mean (SD) 26.1 (5.9) 24.6 (6.0) t = -1.384, df = 122, p = 0.169d
Age at onset of BD (years), median (IQR) 20 (9) 19 (10) U = 1894.0, p = 0.962a
Duration of illness, median (IQR) 9.5 (12) 11.5 (16.75) U = 1739.0, p = 0.407a
In remission, n (%) 19 (35) 31 (46) X2 = 1.515, p = 0.218b
Time in remission, months, median (IQR) 3 (4) 5 (7.25) X2 = 2.511, p = 0.113c
No. of elevated mood episodes, median (IQR) 3 (8.5) 2 (4) U = 1619.0, p = 0.288a
No. of depressive episodes, median (IQR) 4 (9) 3 (8) U = 1716.0, p = 0.604a
Bipolar disorder type, BD I, n (%) 30 (54) 41 (59) X2 = 0.431, p = 0.512b
Psychosis, n (%) 20 (36) 32 (48) X2 = 1.604, p = 0.205b
No. of suicide attempts, median (IQR) 0 (1) 0 (1) U = 600.0, p = 0.053a
Hospitalized (lifetime), n (%) 35 (65) 45 (67) X2 = 0.074, p = 0.786b
No. of admissions, median (IQR) 1 (2.8) 1 (3) U = 1814.0, p = 0.745a
Duration of admissions (months), median (IQR) 1.5 (4.2) 3.3 (5) U = 568.0, p = 0.056a
MARS score, median (IQR) 8 (5) 7 (3) U = 915.5, p = 0.010a Diff. in mean rank = 15.17
Years of education, mean (SD) 13.5 (2.6) 15.1 (2.9) t = 3.307, df = 123, p = 0.001d Cohen’s d = 0.596
Currently employed/full time students, n (%) 12 (21) 31 (45) X2 = 7.564, p = 0.006b Phi = -0.246
Marital status (married/living as married), n (%) 20 (36) 26 (38) X2 = 0.051, p = 0.821
GAF S, mean (SD) 52.9 (10.7) 59.7 (11.1) t = 3.458, df = 123, p = 0.001d Cohen’s d = 0.624
GAF F, mean (SD) 50.3 (11.3) 57.2 (12.1) t = 3.112, df = 123, p = 0.002d Cohen’s d = 0.561
IQR = interquartile range. aMann Whitney U-test, bChi-square test, cLog rank (Mantel Cox) test, dStudent’s t-test.
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excessive substance use group could also be interpreted
as reduced compliance, as shorter admissions may be an
expression of treatment non-compliance. Alternatively,
inpatient treatment facilities are not optimal for treating
BD patients with excessive substance use which may
lead to shorter inpatient treatment. Shorter durations of
psychiatric hospital admissions among patients with
comorbid mental illness and SUD have also been found
in earlier studies [86].
We did not find evidence that the presence of exces-
sive substance use was associated with more severe BD
specific disease characteristics. Earlier studies mainly
investigated DSM-IV SUD, which is more narrowly
defined than the present study’s excessive substance use
category. However, when we analyzed the narrowly
defined SUD group, we did not find different results
compared to the excessive substance use group. Further-
more, we found that the substance use levels among
patients with excessive use were similar to patients with
SUDs. Comparing our results with studies investigating
SUD should therefore be relevant. The present lack of
association between excessive substance use and current
affective symptomatology is in line with several other
studies finding no differences across groups defined by
SUD in these variables [18,50]. It has also been hypothe-
sized that SUD may trigger BD in individuals without a
great constitutional vulnerability for the disorder
[48,87]. Thus, a lack of worsening of BD illness charac-
teristics in the presence of SUD may be explained by a
lower vulnerability. Our finding of no relationship
between excessive substance use and an earlier onset of
the BD is consistent with some studies [55] but in con-
trast to others [29], and these discrepancies are difficult
to explain. The present lack of significant differences in
remission variables was unexpected, since prolonged
affective episodes are found quite consistently by earlier
research [20]. However, there were numerical differ-
ences between the groups in the expected direction on
these variables, so this difference could reach statistical
significance in a larger sample. Furthermore, the present
finding of no relationship between excessive substance
use and number of affective episodes is in line with pre-
vious research [49] although this is sparsely investigated.
Finally, the similar distribution of bipolar subtypes
across the groups in our study converges with some stu-
dies [20,83], but is contrary to those finding higher SUD
rates in bipolar I disorder compared to bipolar II disor-
der [1,6]. Our findings of no differences in BD illness
severity between patients with or without excessive sub-
stance use is in accordance with a recent study on BD I
disorder with or without SUD on several proxies for BD
severity [27].
The trend towards increased suicidality rates as well as
the lower GAF S scores found in the excessive substance
use group in the present study, could be signs of a
poorer general psychiatric outcome not linked to a
more severe BD. Increased suicidality is seen in a num-
ber of psychiatric disorders and has been found asso-
ciated with SUD alone [88], and with the combination
of SUD and a variety of psychiatric disorders [89-91].
Thus it appears reasonable to link the increased suicid-
ality more to the excessive substance use per se than to
a more severe BD course. The lower GAF S scores in
our excessive substance use group were not reflected in
increased symptoms as measured by the IDS and the
YMRS as could be expected, and may also be directly
related to the substance use itself or to the burden of
having two disorders. In summary, excessive substance
use does not appear to be related to more severe speci-
fic BD illness characteristics, but to a more severe gen-
eral psychiatric outcome in terms of worse global
clinical features unspecific to psychiatric diagnosis and
frequently seen in association with substance abuse
alone.
Our finding concerning psychosis is in accordance
with previous studies reporting a lack of association
between SUD and higher lifetime rates of psychosis in
BD [18]. This is not surprising given that these studies
did not specifically investigate the use of cannabis and
centrally stimulating agents known to induce psychotic
symptoms during intoxication [92,93] and increase the
risk of psychotic disorders [94,95]. The lack of associa-
tion between psychosis and excessive use of these psy-
chosis inducing substances found in the present study is
somewhat surprising, but could be related to a high psy-
chosis frequency in general in BD patients, thereby
reducing the relative effect of substance use.
The present study’s approach of adding patients with a
SUD-subthreshold excessive substance use to the SUD
group has additional value, in that we demonstrate that
SUD criteria are not necessarily the appropriate cut-off
when addressing and assessing harmful substance use in
BD. Our findings may also have important implications
for treatment of BD patients with excessive substance
use. Because of the increased functional impairment and
treatment non-compliance associated with excessive
substance use, substance use should be targeted in treat-
ment before the clinical signs of abuse or dependence
have developed. Our findings further demonstrate that
patients with a considerable amount and frequency of
substance use may not necessarily fulfill SUD diagnostic
criteria.
The inconsistency revealed in the literature regarding
differences in clinical and functional characteristics
between BD with and without SUD is somewhat unex-
pected, as several papers including reviews of the topic
generally state that there is consistent evidence that a
comorbid SUD is associated with more severe features.
Lagerberg et al. BMC Psychiatry 2010, 10:9
http://www.biomedcentral.com/1471-244X/10/9
Page 6 of 9
This is a relatively new field, thus citation and publica-
tion biases may be a problem. Studies also vary to a
great extent in operationalizations and methodology,
which may explain some of the discrepancies. Further-
more, studies setting out to answer questions about the
associations between comorbid SUD and outcome in
BD patients are few compared to studies that focus on
other issues and report relationships between comorbid
SUD and outcome as secondary findings. Also, since
only a few studies display effect sizes in addition to sig-
nificance levels, little is known about the strength of the
associations. Thus, there is a great need for more well-
designed and hypothesis-driven studies addressing this
question as well as future efforts to agree on
methodology.
The present study has some limitations. The sample in
the present study was too small to investigate current
use levels or non-alcoholic substance types separately.
Furthermore, since this is a cross-sectional study, no
conclusions of causality may be drawn regarding the
association between excessive substance use and the
functional level. Thus, whether these relationships are
due to negative effects from the excessive substance use,
or related socioeconomic factors, cannot be determined.
Also, the sample size is relatively small, with an
increased risk for type II errors. However, there are few
substantial numerical differences between the groups,
thus an increase in sample size would not lead to addi-
tional significant differences. This is a well characterized
catchment area study, covering both in- and outpatient
units including substance abuse clinics.
Conclusions
The current findings show that there is a significant
increase in illicit substance use in BD compared to gen-
eral population with an OR of 3. Patients with excessive
substance use have indications of impaired functioning
and some signs of a more severe general psychiatric out-
come, but not worse illness course characteristics or
current symptom levels. This has implications for cur-
rent treatment and should lead to more research into
the underlying psychopathological mechanisms.
Additional file 1: Additional file1provides an overview table of the
literature reported in the background section concerning the effect
of substance use disorders on BD. The table is organized in two parts;
Part I: “Reported effects of substance use disorders on measures of
functioning and general psychopathology”, and Part II: “Reported effects
of substance use disorders on measures of illness course and clinical
characteristics specific to bipolar disorder”. Some of the reviewed studies
appear in both Part I and Part II.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-244X-10-9-
S1.DOC ]
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Abstract 
Objective: To investigate which factors are associated with age at onset in bipolar disorder with a specific focus 
on excessive alcohol and cannabis use, and the sequence of the onsets of excessive substance use and bipolar 
disorder.  
Methods: We investigated a naturalistic sample of 151 patients with bipolar I and II disorder receiving 
psychiatric treatment. Whether the presence of excessive substance use prior to bipolar disorder onset or the type 
of substance used (alcohol or cannabis) was associated with differences in age at onset was investigated using 
hierarchical, multiple linear regression analyses, adjusting for potential confounders.  
Results: Patients with excessive alcohol use had a significantly later onset compared to patients with excessive 
cannabis use. Excessive general substance use prior to bipolar disorder onset was associated with a later onset. 
However, excessive cannabis use was associated with an earlier onset whether it preceded or followed bipolar 
disorder onset, also after adjusting for possible confounders. Excessive use of alcohol or other substances was 
not independently associated with age at onset in multivariate analyses.  
 
Conclusions: Alcohol use was associated with a later onset compared to cannabis use, suggesting different 
relationships to the onset of bipolar disorder. Lifetime use of cannabis predicted an earlier onset, independent of 
the sequence of onsets. This indicates that an early onset may increase the risk of cannabis use and that cannabis 
use may trigger bipolar disorder in vulnerable individuals. 
Key words: Bipolar disorder, age at onset, cannabis
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Introduction 
The age at onset (AAO) of bipolar disorder (BD) varies from adolescence to mid-adulthood 1, but the reasons for 
the variation are not fully known. Recent studies find differences in AAO between research sites, with early 
AAO more often reported from US studies than from European  studies 2-4 even though there are exceptions 3;5;6. 
These variations have been attributed to factors ranging from differences in genetic loading to recruitment biases 
or methodological discrepancies 2;6;7 such as the definition of illness onset.  
However, several other factors have been shown to affect AAO in BD. A family history of affective disorder has 
been associated with an early onset8-10. Most studies find a similar AAO for men and women 11, while some 
report earlier onsets in females 12;13, and others earlier onsets in men with BD I 3. The subtypes of BD (BD I and 
II) appear to have a similar AAO 14; however, earlier onsets in either BD I or II was also recently reported 3;7. In 
addition, experiences of childhood trauma was associated with an earlier onset15;16.  
The relationship between substance abuse and AAO in BD is poorly understood. The risk for substance abuse 
(especially of illicit substances) appears to be increased for patients with childhood- and adolescent onset 
compared to adult onset 13;17-21, and it has been hypothesized that AAO and substance abuse may share a 
common genetic etiology 13. These studies, however, did not differentiate between the types of substances used. 
Alcohol and cannabis are the two most frequently used substances in BD 22-25. To the best of our knowledge the 
association between type of substance of abuse (alcohol or cannabis) and AAO has not been investigated in 
previous studies.  
Substance abuse may both be a cause and a consequence of early BD onset. One line of research has investigated 
whether differences in AAO depend on the sequence of the onsets of BD and substance abuse. A later onset has 
been found among patients with substance abuse that precedes the BD 26-32. There is also evidence for a less 
severe clinical course 28;33-35 and lower rates of family history of affective illness 27 in BD secondary to substance 
abuse. This has lead to the hypothesis that substance abuse could be necessary for a manifestation of BD in these 
individuals 27;28;33. Most studies have focused on either alcohol abuse or substance abuse in general, and the 
potential to precipitate BD has been proposed for both alcohol 33;36, cannabis 29 and even for any substance of 
abuse 35.  
The pharmacological effects of various substances of abuse are often different, and alcohol and cannabis appear 
to have different effects on the course of an established BD. In a prospective study, cannabis use coincided with 
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or preceded hypomanic or manic symptoms, while alcohol use coincided with or preceded depressive symptoms 
37. Recently, there has been focus on the relationship between BD and cannabis use in prospective epidemiologic 
studies. These indicate that cannabis use in the general population is associated with development of manic 
symptoms 38, and that lifetime cannabis use is associated with a fivefold increase in the risk of developing BD 39.  
Only one study has investigated the sequence of the onsets of BD and cannabis use disorders and its relationship 
to AAO. This indicated that patients with a primary cannabis use disorder had a later onset compared to patients 
with no cannabis use disorder or a secondary cannabis use disorder 29. This has not been replicated, and there is a 
need for further studies that simultaneously evaluate the associations between AAO and excessive alcohol or 
cannabis use. It is here of particular interest whether or not the excessive substance use was present before the 
BD onset.  
In the present study we investigated a sample of 151 BD patients. We had the following research questions:  
1) Does AAO differ between patients with excessive alcohol use, excessive cannabis use and patients using 
neither of these substances?  
2) Do type of excessive substance use (i.e. alcohol or cannabis) and the presence of excessive substance use prior 
to the BD onset independently predict AAO after adjusting for possible confounders?  
 
Methods and materials 
Participants 
A hundred and fifty-one patients with DSM-IV diagnosed bipolar disorder (BD I n=91 and BD II n=60) 
participated in the study. This patient sample is part of an ongoing study of schizophrenia and BD (the 
Thematically Organized Psychosis (TOP) study). Patients were recruited consecutively from the psychiatric units 
(in- and outpatient) of the three major hospitals in Oslo from 2003 to 2008. Participants were excluded if they 
had a history of moderate/severe head injury, neurological disorder, developmental delays, age outside of 18–65 
years, or if they did not speak a Scandinavian language. All participants gave informed consent, and the project 
was approved by the Regional Committee for Medical Research Ethics as well as the Norwegian Data 
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Inspectorate. Data on the relationship between AAO, illness severity and time to first treatment for parts of this 
sample are reported elsewhere 7. 
Clinical assessment 
Clinical assessments were carried out by trained clinical psychologists and psychiatrists. Diagnoses were 
established using the Structured Clinical Interview for DSM-IV (SCID), modules A-E (American Psychiatric 
Association, 1994). All interviewers were trained based on the training program at UCLA CA, USA and 
participated in regular diagnostic consensus meetings. A good inter-rater reliability was achieved with an overall 
kappa score of 0.77 (95% CI: 0.60-0.94). AAO was defined as the age when the first SCID-verified affective 
episode (depressive, hypomanic, manic or mixed) began. Sociodemographic and clinical variables were cross-
checked with participants’ medical charts and with information from interviews with close family members if 
relevant. A family history of depression, BD, schizophrenia, and other psychotic disorders among first degree 
relatives (i.e. mother, father, brothers and sisters) was obtained through patient interviews. Patients having a 
minimum of one first-degree relative with one or more psychiatric disorders were considered to have a family 
history. A family history of other psychotic disorders than BD was considered since several recent studies have 
shown common heritability for BD and schizophrenia 40;41. A family history was collected for 148 of the 
patients. Of these, 62 (42%) had a positive family history of any lifetime affective or psychotic disorder; 41 
(27%) of depression, 20 (14%) of BD and 6 (4%) of psychotic disorder. Four patients had a family history of 
both BD and depression, and one patient had a family history of both BD and psychosis. 
 
Substance use assessments 
Each patient reported lifetime substance use (daily, weekly, monthly, or occasional/no use) for all substances for 
the following life periods: 11-15 years, 16-20 years, 21-27 years, 28-44 years, 45-60 years, and 60+ years. 
Patients that either 1) met criteria for a DSM-IV substance use disorder (SUD) or 2) had predominantly daily use 
of alcohol and/or predominantly weekly use of a non-alcoholic substance through at least one of the life periods 
above (i.e. for a minimum of four years) were considered excessive substance users and included as such in the 
subsequent analyses. In an earlier study, we have shown that the use patterns and correlates of excessive 
substance use are similar for patients with SUD and patients with excessive substance use according to definition 
above 42.  
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Age at onset of excessive substance use was deemed to be either 1) the age when DSM-IV abuse/dependence 
criteria were first met, or 2) the age when the patient started daily use of alcohol or weekly use of (a) non-
alcoholic substance(s). Twenty-eight patients (19%) had excessive use of alcohol, 24 patients (16%) had 
excessive use of cannabis, and 11 patients used both. Patients who used both were similar to the patients who 
used cannabis only and not to the patients who used alcohol only for all relevant clinical and sociodemographic 
characteristics, and were therefore grouped together with the cannabis-only patients in the bivariate analyses for 
research question 1.  But to further ensure that the differences between the alcohol and cannabis groups were not 
due to the characteristics of the patients using both alcohol and cannabis, follow-up analyses were conducted 
where these patients were excluded. Among the 88 patients with neither excessive alcohol nor cannabis use, 
three patients (3%) had excessive use of other substances. These 88 patients are subsequently referred to as non-
users. 
 
Sequencing of onsets of BD and excessive substance use 
For research question 2, the total sample was subdivided into two groups based on the presence (secondary BD) 
or absence (primary BD) of excessive substance use prior to the first affective episode. This dichotomous 
variable is subsequently referred to as the sequencing of onsets. The small group of patients (n=6) whose onsets 
of the first affective episode and excessive substance use occurred within the same year were categorized as 
secondary BD. This was done because excessive substance use to a greater degree than BD has a gradual rather 
than an abrupt onset. Since all patients in this study eventually were diagnosed with BD, affective episodes 
associated with substance use in patients with no previous BD episode were used as markers for AAO. Using 
these criteria, 117 (77%) patients had primary BD and 34 (23%) had secondary BD. Patients with primary BD 
could theoretically develop excessive substance use after the onset of BD, and data showed that 32 patients 
(21%) subsequently did. Sociodemographic and clinical characteristics in the two groups are described in table 1.  
PLEASE INSERT TABLE 1 HERE. 
 
Statistical Analysis 
All analyses were done using the Statistical Package for the Social Sciences (SPSS) version 16.0. Statistical 
significance was determined using the .05 level and 2-tailed tests of significance. One-way ANOVAs with 
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Tukey’s post-hoc tests were used to compare the groups on continuous variables. Dichotomous variables were 
analyzed with Chi-square tests with corresponding post-hoc analyses performed using Chi-squares with a 
Bonferroni corrected alpha-level for the three group comparisons set to 0.017. Pearson correlations were used to 
assess bivariate associations between the dependent and independent variables. A two-way ANOVA was used to 
investigate the possible interaction effects of type of substance use and sequencing. The contributions of the 
independent variables were then further explored with multiple regression analyses. Possible confounders of the 
relationships between AAO and type of substance or sequencing were chosen on the basis of differences found 
in bivariate analyses and findings from earlier studies.  They were identified as gender, type of BD (I versus II), 
a family history of affective/psychotic disorders, and excessive use of other substances than alcohol or cannabis. 
Possible mediators that did not show significant or trend level effects were not entered in the final model. In the 
present material, age was highly correlated with AAO due to the focus on including mainly non-chronic patients 
in the study. Since preferred substance (alcohol or cannabis) may be a cohort phenomenon and influence AAO, 
age was still entered into the model. This model provided a better mathematical fit despite the colinearity. The 
variance accounted for by some of the other variables was, however, reduced. The analysis was performed 
hierarchically with several steps: first, gender and age; second, BD type and family history of affective/psychotic 
disorders; third, sequencing; and fourth, excessive alcohol and cannabis use. Reported are increase in R2 at each 
step, beta-values, and their corresponding statistics from the final model.  
 
Results 
Patients with excessive alcohol use had a significantly later onset compared to patients with excessive cannabis 
use, and showed a trend in the same direction relative to the non-users (Table 2). Excessive alcohol users and 
non-users were older than the cannabis users. The excessive alcohol users also had a significantly later onset of 
the excessive substance use than the cannabis users. The proportion of patients with a family history of affective 
or psychotic disorders was significantly higher among the cannabis users compared to the alcohol users. There 
was a trend towards a greater proportion of females among the non-users compared to the alcohol users 
(p=0.065). Follow-up analyses excluding patients using both alcohol and cannabis did not give any changes 
regarding group wise differences for age, AAO and age at onset of excessive substance use, or for the proportion 
with BD I or a family history of affective/psychotic disorder. The difference in the proportion with excessive use 
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of other substances was, however, no longer significant (18% vs. 25%, χ2=0.40, p=0.53) implying that excessive 
polysubstance use was a characteristic of the excluded group.  
PLEASE INSERT TABLE 2 HERE.  
AAO was earlier for primary BD compared to secondary BD (21.8±9.0 vs. 25.9±9.8, p=0.02) (Table 1) and for 
cannabis users compared to alcohol users (19.5±5.4 vs. 27.9±11.8, p=0.005) (Table 2) in both primary and 
secondary BD as illustrated by Figure 1. There were no interaction effects between sequencing and type of 
substance use.  
PLEASE INSERT FIGURE 1 HERE 
The bivariate analyses revealed significant correlations between AAO and gender, age, BD type, excessive 
cannabis use, and sequencing (Table 3). 
PLEASE INSERT TABLE 3 HERE 
The multiple regression analysis showed that sequencing and excessive cannabis use significantly predicted 
AAO after adjusting for gender, age, and BD type. Age and BD type also made significant contributions to the 
model, while gender contributed on a trend level (Table 4). Excessive use of alcohol was not a significant 
predictor, nor was family history or excessive use of other substances. Lower age, BD II, primary BD and 
excessive cannabis use independently predicted an earlier onset, with gender and age explaining 29% of the 
variance, type of BD 3%, sequencing 5% and alcohol and cannabis use another 5%, with a total of 41% of the 
variance explained. Without age entered in the analysis, gender explained 5% of the variance, type of BD 3%, 
sequencing 2.5% and alcohol and cannabis use another 13.5%, with a total of 24% of the variance explained. 
Since sequencing was entered before cannabis use in the analyses, cannabis use appeared to predict an earlier 
onset regardless of whether it preceded or followed the onset of the BD. 
PLEASE INSERT TABLE 4 HERE. 
Discussion 
The main finding of the present study was that excessive cannabis use predicted an earlier onset, while 
secondary BD predicted a later onset, after adjusting for possible confounders. Furthermore, excessive alcohol 
users had a later onset compared to excessive cannabis users.  
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We found clear differences between the alcohol users and the cannabis users. In addition to a later onset, the 
alcohol users were older, had a later onset of the excessive use, a lower prevalence of family history and lower 
rates of use of other substances compared to the cannabis users. This has, to our knowledge, not been shown 
before. Our findings also suggest differences in sequencing between the alcohol and the cannabis users; for the 
alcohol users, the mean AAO was earlier than the mean age at onset of the excessive substance use, while for the 
cannabis users the mean AAO was later than the mean age at onset of the excessive substance use. There was, 
however, no interaction effect between type of substance use and sequencing on AAO.  
The later onset in alcohol users compared to cannabis users may indicate that different mechanisms are involved 
in the relationships between the development of BD and these two most frequently used substances. Although 
the present study is cross-sectional and does not allow conclusions of causality, taken together, our findings may 
indicate that cannabis to a greater extent than alcohol influences the onset of BD. This is in line with two recent 
studies on acutely ill patients with a broad spectrum of psychotic disorders, showing that cannabis 
abuse/dependence was associated with an earlier onset of the psychotic disorders after adjusting for 
abuse/dependence of other substances including alcohol 43;44. Our findings indicate that the association between 
AAO and excessive cannabis use is present also in a pure BD sample. This is in line with the growing evidence 
that cannabis use is a risk factor for developing manic symptoms and BD 38;39, while alcohol abuse seems to 
increase the risk for depressive rather than manic symptomatology 37;45. Furthermore, in a recent study on 
prodromes of first manic psychotic episode, 68% of patients were found to have substance use disorders in the 
prodromal phase, of which 82% used cannabis 46. Also, it is fairly well established that cannabis use composes a 
risk factor for the development of psychosis/schizophrenia 47. The fact that schizophrenia and BD have many 
clinical features in common as well as overlapping pathophysiology 48 increases the plausibility that cannabis use 
may act as a risk factor also in BD. 
The association between cannabis use and early onset in the current study was present also after adjusting for 
sequencing, and appears to exist also when the excessive use develops after the BD. This indicates that an early 
onset increases the risk of subsequently developing excessive cannabis use. This is in accordance with earlier 
findings of an association between early BD onset and drug abuse 19;49, which may have several explanations. 
Some authors have proposed that patients with early onset may share a common increased genetic vulnerability 
mediating both BD and excessive drug use 13. Family history did not independently predict AAO in the present 
study. However, the family history rates of affective/psychotic disorders among the cannabis users were high. 
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Having a close family member with a severe psychiatric disorder in addition to experiencing affective episodes 
early in life may also represent a substantial psychosocial burden, leaving the patient at increased risk for illicit 
substance use.  
The present finding that cannabis use predicts an earlier onset regardless of sequencing is in contrast to earlier 
findings of a later onset of BD secondary to cannabis 29. This discrepancy could be due to differences in 
methodology and sample characteristics. One explanation may be the high family history rates in our sample of 
excessive cannabis users, on which no data were presented in the previous study. Higher family history rates 
may indicate high vulnerability for BD, which may interact with excessive cannabis use to cause an early onset 
in these patients. The complex relationship between AAO, type of substance used, sequencing and family history 
should be further explored in a greater sample allowing comparisons on several subgroup levels. 
One possible explanation for the association between early onset of BD and excessive cannabis use could be a 
cohort effect, i.e. that people born in the last decades may be at greater risk for developing excessive cannabis 
use than patients born earlier due to trends in substance use or increased availability. However, since excessive 
cannabis use still predicted AAO after adjusting for age, this cannot explain the finding. The association between 
earlier onsets and cannabis use was also present after adjusting for family history and excessive use of other 
substances. Thus, it is unlikely the present findings can be explained in terms of these potential confounders.  
The present finding that secondary BD predicted a later onset (relative to primary BD) is highly consistent with 
earlier studies 26-32. We also demonstrate that this effect remains significant even after adjusting for several 
variables known to be associated with AAO (gender, BD type, family history, type of substance used), further 
supporting the hypothesis that the excessive substance use may trigger BD. We do not replicate earlier findings 
that family history is associated with AAO 8, or that family history rates are lower in secondary BD compared to 
primary BD 27. We do, however, demonstrate that the family history rates are higher among the cannabis users 
compared to the alcohol users and the non-users. Patients’ reports of family history of psychiatric disorders is a 
somewhat crude measure 50, which may explain these inconsistencies. Furthermore, the full range of 
vulnerability markers and risk factors for BD are not yet known, thus other factors may have confounded the 
results.  
In the multivariate analyses we found that BD II disorder independently predicted an earlier onset, with the same 
trend for female gender. Recent studies on the association between AAO, gender and BD type are somewhat 
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diverging; one study reported earlier onsets in females but no differences regarding BD type 12, while another 
reported that males and BD I had an earlier onset compared to females and BD II 3. The latter finding is in 
contrast to the present study, while the former showed similar results. This suggests that gender and BD type are 
relevant when investigating AAO, but future studies are needed to clarify these questions. Also, the findings of 
the present study suggest that the prevalence of excessive cannabis use could account for differences between 
populations in AAO. 
The present study has some limitations. Data on substance use and illness characteristics including AAO were 
gathered retrospectively, risking recall bias. There is, however, no reason to believe that this should affect the 
subgroups differently. Furthermore, some of the subgroups in the bivariate analyses are small, increasing the risk 
of type II errors. 
 
Conclusion  
Excessive cannabis use is associated with an early onset regardless of whether it precedes or follows the BD, 
while excessive use of alcohol or other substances are not independently associated with AAO. General 
excessive substance use prior to BD onset is associated with a later onset. The relationship between cannabis use 
and BD onset should be further investigated in prospective studies.  
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Table 1. Sociodemographic and clinical characteristics in primary BD and secondary BD 
Primary BD Secondary BD Statistics 
  N=117 N=34   
Age, y, mean (SD) 36.50 (12.2) 33.7 (10.4) t=1.2, df=149, p=0.227a 
AAO, y, mean (SD) 21.8 (9.0) 25.9 (9.8) t=-2.3, df=149, p=0.020a 
Age at onset of excessive substance use, y, mean (SD)* 27.0 (11.6) 20.1 (7.0) t=2.9, df=64, p=0.005a 
Gender, female, n (%) 74 (63.2) 18 (52.9) χ²=1.2, df= 1, p=0.278b 
Type I BD, (%) 68 (58.1) 23 (67.6) χ²=1.0, df=1, p=0.318b 
Family history of affective/psychotic disorder, n (%) 45 (39) 17 (52) χ²=1.6, df=1, p=0.204b 
BD=Bipolar Disorder. AAO=Age at onset of BD. Y=Years. *For the 32 patients with excessive substance use in the primary BD group.  
aStudent's t-test, bChi-square test.  
Significant p-values are typed in bold. 
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Table 4. Multiple regression analysis of the effect of independent variables on age at onset 
Block No., Variable R2 Change Beta (SE) 95% Confidence Interval for B t P value  
Constant 17.33 (10.30 to 24.36) 4.87 <0.001 
1 
Female 0.29 -2.42 (1.27) (-5.43 to -0.17) -1.91 0.058  
Age 0.36 (0.06) (0.25 to 0.46) 6.48 <0.001  
2 
BD I 0.03 -2.73 (1.23) (-5.16 to -0.30) -2.22 0.028  
3 
Secondary BD 0.05 8.20 (1.79) (4.67 to 11.72) 4.59 <0.001  
4 
Excessive cannabis use 0.05 -6.01 (1.8)  (-9.59 to -2.43) -3.32 0.001 
Excessive alcohol use   -0.33 (1.43) (-3.16 to 2.50) -0.23 0.817  
 
Final model, R2=0.41, F=16.65, p<0.001 
Table 3. The correlations between AAO and socio- demographic and 
clinical variables 
Variable AAO 
Age 0.52** 
Gender -0.22** 
BD type (I versus II) -0.19* 
Family history of affective/psychotic disorder  -0.15 
Age at onset of excessive substance use 0.54** 
Excessive cannabis use -0.19* 
Excessive alcohol use 0.13 
Excessive use of other substances -0.14 
Sequencing 0.19* 
AAO=Age at onset. Data are expressed as Pearson correlations 
*p<0.05 
**p<0.01 
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Figure 1. Relationship between AAO, sequencing and type of substance use 
 
AAO=Age at onset, years. BD=bipolar disorder. 
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